https://crcwarriors.org/ 2026-06-18 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-06-18 daily 0.9 https://crcwarriors.org/medicamentos 2026-06-18 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-06-18 daily 0.8 https://crcwarriors.org/noticias 2026-06-18 daily 0.8 https://crcwarriors.org/combinaciones 2026-06-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-06-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-06-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-06-01 monthly 0.7 https://crcwarriors.org/contacto 2026-06-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-06-01 monthly 0.6 https://crcwarriors.org/colabora 2026-06-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07492680/un-estudio-de-bms-986504-en-monoterapia-y-en-combinacion-con-otros-agentes-en-participantes-con-tumores-solidos-avanzados-y-o-metastasicos-con-delecion-homocigotica-de-mtap-mountaintap-5 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07492680/a-study-of-bms-986504-monotherapy-and-in-combination-with-other-agents-in-participants-with-advanced-and-or-metastatic-solid-tumors-with-homozygous-mtap-deletion-mountaintap-5 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06983743/un-estudio-de-eras-0015-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06983743/a-study-of-eras-0015-in-patients-with-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07387068/ensayo-para-evaluar-la-seguridad-y-la-eficacia-preliminar-de-gen1079-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07387068/trial-to-evaluate-the-safety-and-preliminary-efficacy-of-gen1079-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07651007/radioterapia-de-corta-duracion-seguida-de-nalirifox-mas-pucotenlimab-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-mss-pmmr 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07651007/short-course-rt-followed-by-nalirifox-plus-pucotenlimab-as-neoadjuvant-therapy-for-high-risk-locally-advanced-rectal-cancer-with-mss-pmmr 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07639554/optimizacion-de-la-participacion-en-los-programas-de-deteccion-del-cancer-colorrectal-mediante-la-invitacion-directa-de-los-pacientes-que-no-responden-a-las-invitaciones-iniciales-realizada-por-los 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07639554/optimizing-participation-in-colorectal-cancer-screening-by-direct-invitation-of-non-responders-by-general-practitionners 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07653685/un-estudio-clinico-de-tqb2930-inyectable-y-quimioterapia-con-o-sin-bevacizumab-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07653685/a-clinical-study-of-tqb2930-injection-and-chemotherapy-with-or-without-bevacizumab-in-the-treatment-of-advanced-colorectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06618287/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-los-niveles-del-farmaco-y-la-eficacia-preliminar-de-las-combinaciones-de-bms-986507-en-participantes-adultos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06618287/a-study-to-evaluate-the-safety-tolerability-drug-levels-and-preliminary-efficacy-of-bms-986507-combinations-in-adult-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06431594/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-clinica-de-gsk5733584-para-inyeccion-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06431594/a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-clinical-activity-of-gsk5733584-for-injection-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07539285/un-estudio-de-hdm2024-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07539285/a-study-of-hdm2024-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124793/un-estudio-de-la-terapia-combinada-con-ibi363-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07124793/a-study-of-ibi363-combination-therapy-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05687682/seguridad-de-la-infusion-de-am-928-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05687682/safety-of-am-928-infusion-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06014502/estudio-para-evaluar-el-tratamiento-con-imgs-001-en-pacientes-con-tumores-solidos-avanzados-recurrentes-o-refractarios 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06014502/study-to-evaluate-imgs-001-treatment-in-patients-with-relapsed-or-refractory-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07444814/estudio-que-evalua-la-seguridad-y-la-eficacia-de-hwk-007-un-conjugado-anticuerpo-farmaco-dirigido-a-ptk7-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07444814/study-evaluating-the-safety-and-efficacy-of-hwk-007-a-ptk7-directed-antibody-drug-conjugate-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06415487/ace2016-en-pacientes-adultos-con-tumores-solidos-localmente-avanzados-o-metastasicos-que-expresan-el-receptor-del-factor-de-crecimiento-epidermico-egfr 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06415487/ace2016-in-adult-subjects-with-locally-advanced-or-metastatic-solid-tumors-expressing-epidermal-growth-factor-receptor-egfr 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914376/seguridad-de-la-inyeccion-con-virus-vaccinia-oncolitico-recombinante-que-expresa-il-21-humana-hv01-en-tumores-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05914376/safety-of-recombinant-human-il-21-expressing-oncolytic-vaccinia-virus-injection-hv01-in-advanced-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04412616/zz06-en-pacientes-adultos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04412616/zz06-in-adult-patients-with-advanced-solid-tumor-malignancies 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210815/un-estudio-de-hlx42-en-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210815/a-study-of-hlx42-in-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04305795/un-estudio-abierto-que-utiliza-la-fotoinmunoterapia-asp-1929-en-combinacion-con-terapia-anti-pd1-en-tumores-solidos-avanzados-que-expresan-egfr 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04305795/an-open-label-study-using-asp-1929-photoimmunotherapy-in-combination-with-anti-pd1-therapy-in-egfr-expressing-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06710132/estudio-del-adc-anti-ceacam5-m9140-en-participantes-con-tumores-solidos-avanzados-proceade-pantumor 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06710132/study-of-anti-ceacam5-adc-m9140-in-participants-with-advanced-solid-tumors-proceade-pantumor 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622524/un-estudio-de-fase-i-de-cs5007-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622524/a-phase-i-study-of-cs5007-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05948865/un-estudio-de-fase-i-de-cpo301-en-pacientes-adultos-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05948865/a-phase-1-study-of-cpo301-in-adult-patients-with-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07510841/inyeccion-de-jy016-en-pacientes-con-tumores-solidos-avanzados-que-expresan-egfr 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07510841/jy016-injection-in-patients-with-advanced-solid-tumors-expressing-egfr 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038343/aventine-1-estudio-de-avzo-1418-como-agente-unico-y-en-combinacion-terapeutica-en-pacientes-con-tumores-solidos-avanzados-localmente-o-metastasicos-avzo-1418-1001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07038343/aventine-1-study-of-avzo-1418-as-a-single-agent-and-in-combination-therapy-in-patients-with-locally-advanced-or-metastatic-solid-tumors-avzo-1418-1001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05498428/un-estudio-de-amivantamab-en-participantes-con-tumores-solidos-avanzados-o-metastasicos-incluidos-los-canceres-de-pulmon-no-microcitico-con-mutaciones-en-el-receptor-del-factor-de-crecimiento 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05498428/a-study-of-amivantamab-in-participants-with-advanced-or-metastatic-solid-tumors-including-epidermal-growth-factor-receptor-egfr-mutated-non-small-cell-lung-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07181473/un-estudio-para-evaluar-la-seguridad-la-farmacocinetica-y-la-eficacia-de-tj101-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07181473/a-study-to-evaluate-the-safety-pharmacokinetics-and-efficacy-of-tj101-in-patients-with-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05533697/estudio-de-mrna-4359-administrado-solo-y-en-combinacion-con-bloqueo-de-puntos-de-control-inmunitarios-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05533697/study-of-mrna-4359-administered-alone-and-in-combination-with-immune-checkpoint-blockade-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07136779/ensayo-clinico-de-fase-i-con-vbc101-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07136779/first-in-human-trial-of-vbc101-in-participants-with-advanced-solid-tumor-malignancies 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06960395/seguridad-y-eficacia-preliminar-de-vir-5525-y-vir-5525-pembrolizumab-en-participantes-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06960395/safety-and-preliminary-efficacy-of-vir-5525-and-vir-5525-pembrolizumab-in-participants-with-locally-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT00045201/erlotinib-clorhidrato-e-irinotecan-clorhidrato-en-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT00045201/erlotinib-hydrochloride-and-irinotecan-hydrochloride-in-treating-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07327411/cetuximab-combinado-con-el-regimen-prag-en-el-tratamiento-de-tumores-solidos-avanzados-y-refractarios-egfr-positivos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07327411/cetuximab-combined-with-prag-regimen-in-the-treatment-of-egfr-positive-advanced-refractory-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04626635/un-ensayo-clinico-para-determinar-la-seguridad-de-regn7075-y-su-eficacia-en-combinacion-con-cemiplimab-en-participantes-adultos-con-cancer-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04626635/a-trial-to-find-out-how-safe-regn7075-is-and-how-well-it-works-in-combination-with-cemiplimab-for-adult-participants-with-advanced-cancers 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06115642/un-estudio-de-fase-i-para-evaluar-la-seguridad-la-tolerabilidad-y-la-farmacocinetica-de-hlx43-en-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06115642/a-phase-i-study-to-evaluate-the-safety-tolerability-and-pk-of-hlx43-in-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06758557/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-la-inyeccion-de-hb0025-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06758557/a-study-to-evaluate-the-safety-and-efficacy-of-hb0025-injection-in-patients-with-advanced-solid-tumor 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617727/un-estudio-de-fase-i-de-jskn021-en-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07617727/a-phase-i-study-of-jskn021-in-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612137/estudio-de-la-terapia-combinada-con-ibi3005-en-participantes-con-tumores-solidos-irresecables-localmente-avanzados-o-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612137/study-of-ibi3005-combination-therapy-in-participants-with-unresectable-locally-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05341492/terapia-car-t-anti-egfr-b7h3-en-cancer-de-pulmon-y-cancer-de-mama-triple-negativo 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05341492/egfr-b7h3-car-t-on-lung-cancer-and-triple-negative-breast-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05981703/un-estudio-que-investiga-el-uso-de-bgb-26808-en-monoterapia-o-en-combinacion-con-tislelizumab-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05981703/a-study-investigating-bgb-26808-alone-or-in-combination-with-tislelizumab-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06384352/un-estudio-de-fase-i-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-eficacia-de-yl211-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06384352/a-phase-i-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-efficacy-of-yl211-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05541822/evaluar-la-eficacia-la-seguridad-la-tolerabilidad-y-el-perfil-farmacocinetico-de-abn401-en-pacientes-con-tumores-solidos-avanzados-que-presenten-alteraciones-en-c-met 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05541822/to-evaluate-the-efficacy-safety-tolerability-and-pharmacokinetic-profile-of-abn401-in-patients-with-advanced-solid-tumors-harboring-c-met-dysregulation 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07345637/estudio-de-fase-i-de-fxs887-en-el-tratamiento-de-tumores-solidos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07345637/phase-i-study-of-fxs887-in-the-treatment-of-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06992687/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-hb0052-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06992687/a-study-to-evaluate-the-safety-and-efficacy-of-hb0052-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07417501/lenvatinib-mas-un-inhibidor-de-pd-1-para-tumores-solidos-avanzados-con-amplificacion-de-11q13 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07417501/lenvatinib-plus-pd-1-inhibitor-for-advanced-solid-tumors-with-11q13-amplification 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06488950/un-estudio-de-los-linfocitos-infiltrantes-tumorales-en-tumores-solidos-avanzados-dfgd 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06488950/a-study-of-til-in-advanced-solid-tumors-dfgd 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06171750/estudio-de-fase-i-de-tolododequina-alfa-ank-101-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06171750/phase-i-study-of-tolododekin-alfa-ank-101-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05919537/estudio-de-un-anticuerpo-anti-her3-hmbd-001-con-o-sin-quimioterapia-en-pacientes-con-tumores-solidos-que-presenten-una-fusion-de-nrg1-o-una-mutacion-de-her3 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05919537/study-of-an-anti-her3-antibody-hmbd-001-with-or-without-chemotherapy-in-patients-with-solid-tumors-harboring-an-nrg1-fusion-or-her3-mutation 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06090266/un-estudio-de-or502-un-anticuerpo-monoclonal-dirigido-contra-lilrb2-en-monoterapia-y-en-combinacion-con-agentes-antineoplasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090266/a-study-of-or502-a-monoclonal-antibody-targeting-lilrb2-alone-and-in-combination-with-anticancer-agents 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03993873/estudio-de-tpx-0022-en-pacientes-con-cancer-de-pulmon-no-microcitico-avanzado-cancer-gastrico-o-tumores-solidos-que-presenten-alteraciones-geneticas-en-met 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03993873/study-of-tpx-0022-in-patients-with-advanced-nsclc-gastric-cancer-or-solid-tumors-harboring-genetic-alterations-in-met 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06928922/vacuna-en-polvo-seca-de-arnm-inhalable-que-contiene-antigenos-tumorales-en-pacientes-con-cancer-de-pulmon-avanzado-y-metastasis-pulmonares-de-tumores-solidos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06928922/inhaled-mrna-tumor-associated-antigen-dry-powder-vaccine-in-advanced-lung-cancer-and-lung-metastasis-of-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06414460/estudio-de-ism3412-en-participantes-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06414460/study-of-ism3412-in-participants-with-locally-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06707610/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-pk-y-la-actividad-antitumoral-de-alk202-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06707610/a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-pk-and-antitumor-activity-of-alk202-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05417321/un-estudio-que-evalua-la-seguridad-y-la-eficacia-de-hb0036-en-sujetos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05417321/a-study-evaluating-the-safety-and-efficacy-of-hb0036-in-subjects-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04794699/estudio-de-ide397-en-participantes-con-tumores-solidos-que-presentan-delecion-de-mtap 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04794699/study-of-ide397-in-participants-with-solid-tumors-harboring-mtap-deletion 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07436728/un-estudio-de-tak-505-en-adultos-con-tumores-solidos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07436728/a-study-of-tak-505-in-adults-with-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06694480/estudio-de-fid-022-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06694480/study-of-fid-022-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04370587/un-estudio-clinico-de-mvr-t3011-t3011-administrado-intratumoralmente-ya-sea-como-agente-unico-o-en-combinacion-con-pembrolizumab-intravenoso-en-participantes-con-tumores-solidos-avanzados-o 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04370587/a-clinical-study-of-intratumoral-mvr-t3011-t3011-given-as-a-single-agent-and-in-combination-with-intravenous-pembrolizumab-in-participants-with-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06991478/inyeccion-de-sk-nk-en-pacientes-con-tumores-solidos-avanzados-que-presentan-ascitis-maligna 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06991478/sk-nk-injection-in-patients-with-advanced-solid-tumors-accompanied-by-malignant-ascites 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07382531/inyeccion-de-oh2-en-combinacion-con-inyeccion-de-bs006-para-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07382531/oh2-injection-in-combination-with-bs006-injection-for-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820424/seguridad-y-eficacia-preliminar-de-la-terapia-con-celulas-car-t-anti-cdh17-en-pacientes-con-tumores-solidos-avanzados-cdh17-positivos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820424/safety-and-preliminary-efficacy-of-anti-cdh17-car-t-cell-therapy-in-patients-with-cdh17-positive-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05951608/un-estudio-clinico-de-fase-ib-ii-de-ak127-en-combinacion-con-ak112-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05951608/a-phase-ib-ii-clinical-study-of-ak127-in-combination-with-ak112-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02099058/un-estudio-que-evalua-la-seguridad-la-farmacocinetica-pk-y-la-eficacia-preliminar-de-abbv-399-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02099058/a-study-evaluating-the-safety-pharmacokinetics-pk-and-preliminary-efficacy-of-abbv-399-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04093466/un-estudio-de-fase-i-de-cx1003-kanitinib-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04093466/a-phase-1-study-of-cx1003-kanitinib-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06596473/un-estudio-de-bg-c477-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06596473/a-study-of-bg-c477-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05979155/un-estudio-de-nwy001-en-sujetos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05979155/a-study-of-nwy001-in-subjects-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06803680/un-estudio-de-bgb-b455-en-adultos-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06803680/a-study-of-bgb-b455-in-adults-with-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06373406/un-estudio-de-mhb036c-para-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373406/a-study-of-mhb036c-for-advanced-solid-tumor 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07292038/seguridad-y-farmacocinetica-de-nm6603-en-pacientes-chinos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07292038/safety-and-pharmacokinetics-of-nm6603-in-chinese-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07541001/prl3-zumab-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07541001/prl3-zumab-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06598800/estudio-de-bg-t187-en-monoterapia-y-en-combinacion-con-otros-agentes-terapeuticos-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06598800/study-of-bg-t187-alone-and-in-combination-with-other-therapeutic-agents-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07558200/estudio-de-fase-ia-ib-con-fxb0871-en-monoterapia-en-tumores-solidos-avanzados-localmente-o-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07558200/phase-ia-ib-study-of-fxb0871-monotherapy-in-locally-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05662397/un-estudio-de-hst-1011-administrado-como-monoterapia-y-en-combinacion-con-un-anticuerpo-anti-pd1 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05662397/a-study-of-hst-1011-given-as-monotherapy-and-in-combination-with-an-anti-pd1-antibody 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07067567/un-estudio-de-ak146d1-para-inyeccion-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067567/a-study-of-ak146d1-for-injection-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07354711/un-estudio-de-fase-i-con-3h-10000-en-pacientes-con-tumores-solidos-irresecables-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07354711/a-first-in-human-study-of-3h-10000-in-patients-with-unresectable-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914545/un-estudio-de-fz-ad004-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914545/a-study-of-fz-ad004-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424665/un-estudio-de-fz-ad005-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424665/a-study-of-fz-ad005-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07231081/estudio-de-fase-i-de-las-celulas-car-t-tx103-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07231081/phase-i-study-of-tx103-car-t-cells-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06428331/un-estudio-de-skb518-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06428331/a-study-of-skb518-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07439094/un-estudio-de-fase-i-en-humanos-con-ckd-703-en-tumores-solidos-avanzados-y-cancer-de-pulmon-no-microcitico 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07439094/a-first-in-human-study-of-ckd-703-in-advanced-solid-tumors-and-non-small-cell-lung-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07265622/estudio-de-fase-i-con-7mw4911-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07265622/first-in-human-study-of-7mw4911-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787950/estudio-clinico-de-asn-3186-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06787950/clinical-study-of-asn-3186-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07448116/estudio-de-mcla-129-en-combinacion-con-ensartinib-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07448116/study-of-mcla-129-in-combination-with-ensartinib-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05888857/medi5752-en-pacientes-con-tumores-solidos-que-presentan-estructuras-linfoides-terciarias-maduras 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05888857/medi5752-in-patients-with-mature-tertiary-lymphoid-structures-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06049212/sacituzumab-tirumotecan-mk-2870-como-monoterapia-y-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos-avanzados-mk-2870-008 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06049212/sacituzumab-tirumotecan-mk-2870-as-monotherapy-and-in-combination-with-pembrolizumab-in-participants-with-advanced-solid-tumors-mk-2870-008 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05174637/un-estudio-de-fda018-adc-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05174637/a-study-of-fda018-adc-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07251166/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-eficacia-preliminar-de-gensci140-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07251166/a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-of-gensci140-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05812027/un-estudio-de-cribado-para-recolectar-muestras-de-taa-hla-y-perdida-de-heterocigosidad-de-hla-en-pacientes-con-tumores-solidos-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05812027/a-screening-study-to-collect-samples-for-taa-hla-hla-loss-of-heterozygosity-in-patients-with-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06233942/estudio-de-fase-1a-1b-el-primero-en-humanos-de-bg-c9074-en-monoterapia-y-en-combinacion-con-otras-terapias-antineoplasicas-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06233942/phase-1a-1b-first-in-human-study-of-bg-c9074-alone-and-in-combination-with-other-anticancer-therapies-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06561685/un-estudio-de-ly4050784-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06561685/a-study-of-ly4050784-in-participants-with-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07645742/estudio-piloto-sobre-el-ayuno-intermitente-en-combinacion-con-inhibidores-de-los-puntos-de-control-inmunitario 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07645742/pilot-study-of-intermittent-fasting-with-immune-checkpoint-inhibitors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04693468/talazoparib-y-palbociclib-axitinib-o-crizotinib-para-el-tratamiento-de-tumores-solidos-avanzados-o-metastasicos-ensayo-talacom 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04693468/talazoparib-and-palbociclib-axitinib-or-crizotinib-for-the-treatment-of-advanced-or-metastatic-solid-tumors-talacom-trial 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06712680/un-estudio-de-fase-i-ii-de-la-monoterapia-con-hyp-6589-en-el-tratamiento-de-tumores-solidos-avanzados-y-en-combinacion-con-inhibidores-de-la-tirosina-quinasa-en-el-tratamiento-de-pacientes-con-cpnp 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06712680/a-phase-i-ii-study-of-hyp-6589-monotherapy-in-treating-advanced-solid-tumors-and-in-combination-with-tyrosine-kinase-inhibitors-in-treating-patients-with-advanced-nsclc-positive-for-driver-genes 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06943521/un-estudio-de-mt-4561-en-pacientes-con-diversos-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06943521/a-study-of-mt-4561-in-patients-with-various-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04299191/estudio-de-lam561-en-pacientes-pediatricos-con-glioma-maligno-y-otros-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04299191/study-of-lam561-acid-in-pediatric-patients-with-malignant-glioma-and-other-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06636435/un-estudio-de-fase-i-el-primero-en-humanos-de-cba-1205-un-anticuerpo-monoclonal-anti-dlk1-en-pacientes-con-tumores-solidos-avanzados-carcinoma-hepatocelular-chc-melanoma-y-cancer-pediatrico 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06636435/a-phase-i-first-in-human-study-of-cba-1205-anti-dlk1-monoclonal-antibody-in-patients-with-advanced-solid-tumors-hepatocellular-carcinoma-hcc-melanoma-and-pediatric-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349160/seguridad-y-eficacia-de-los-linfocitos-infiltrantes-tumorales-metabolicamente-potenciados-meta10-til-para-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349160/safety-and-efficacy-of-metabolically-armed-tumor-infiltrating-lymphocytes-meta10-til-for-the-treatment-of-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04898543/quilt-3-076-estudio-de-celulas-m-cenk-autologas-en-sujetos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04898543/quilt-3-076-study-of-autologous-m-cenk-in-subjects-with-locally-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05103345/estudio-de-sgn1-administrado-mediante-inyeccion-intratumoral-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05103345/study-of-sgn1-administered-via-intratumoral-injection-in-patients-with-advanced-solid-tumor 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06156332/un-estudio-de-surufatinib-en-combinacion-con-serplulimab-en-el-tratamiento-de-tumores-solidos-avanzados-con-diferenciacion-neuroendocrina-que-no-respondieron-a-la-terapia-estandar 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06156332/a-study-of-surufatinib-combined-with-serplulimab-in-the-treatment-of-advanced-solid-tumors-with-neuroendocrine-differentiation-that-failed-standard-therapy 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07253116/un-estudio-clinico-de-fase-i-ii-de-wj22096-en-comprimidos-en-pacientes-con-tumores-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253116/a-phase-i-ii-clinical-study-of-wj22096-tablets-in-patients-with-advanced-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05791448/au409-para-el-tratamiento-de-canceres-primarios-avanzados-de-higado-o-tumores-solidos-con-metastasis-hepaticas 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05791448/au409-for-the-treatment-of-advanced-primary-liver-cancers-or-solid-tumor-with-liver-metastatic-disease 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05269381/vacuna-basada-en-peptidos-neoantigenicos-personalizados-en-combinacion-con-pembrolizumab-para-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05269381/personalized-neoantigen-peptide-based-vaccine-in-combination-with-pembrolizumab-for-treatment-of-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04785196/apg-115-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-liposarcoma-avanzado-o-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04785196/apg-115-in-combination-with-pd-1-inhibitor-in-patients-with-advanced-liposarcoma-or-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07473726/un-estudio-clinico-de-fase-i-para-evaluar-la-seguridad-la-tolerabilidad-y-la-farmacocinetica-de-hlx48-en-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07473726/a-phase-i-clinical-study-to-evaluate-the-safety-tolerability-and-pk-of-hlx48-in-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06298058/un-ensayo-clinico-de-sibp-a13-inyectable-en-el-tratamiento-de-pacientes-con-tumores-solidos-malignos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06298058/a-clinical-trial-of-sibp-a13-injection-in-the-treatment-of-advanced-malignant-solid-tumor-patients 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030712/un-estudio-clinico-de-mk-8294-en-participantes-con-tumores-solidos-avanzados-mk-8294-001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030712/a-clinical-study-of-mk-8294-in-participants-with-advanced-solid-tumors-mk-8294-001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06730581/utidelona-en-capsulas-como-monoterapia-para-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06730581/utidelone-capsule-monotherapy-for-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06669117/ensayo-fih-de-vert-002-en-pacientes-con-tumores-solidos-avanzados-localmente-o-metastasicos-con-alteraciones-en-met 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06669117/fih-trial-of-vert-002-in-patients-with-locally-advanced-or-metastatic-solid-tumors-with-met-alterations 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05918445/pm8002-en-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05918445/pm8002-in-the-treatment-of-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06188702/s095035-como-agente-unico-y-en-combinacion-en-participantes-adultos-con-tumores-solidos-avanzados-o-metastasicos-con-delecion-de-mtap 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06188702/s095035-as-a-single-agent-and-in-combination-in-adult-participants-with-advanced-or-metastatic-solid-tumors-with-deletion-of-mtap 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06695689/un-estudio-clinico-iniciado-por-el-investigador-sobre-la-inyeccion-de-lm303-para-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06695689/an-investigator-initiated-clinical-study-of-lm303-injection-for-the-treatment-of-advanced-solid-tumours 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05378425/un-estudio-de-ntx-1088-un-anticuerpo-monoclonal-dirigido-al-receptor-del-poliovirus-pvr-cd155-como-monoterapia-y-en-combinacion-con-pembrolizumab 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05378425/a-study-of-ntx-1088-a-monoclonal-antibody-targeting-the-poliovirus-receptor-pvr-cd155-as-monotherapy-and-combined-with-pembrolizumab 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06548672/un-estudio-para-evaluar-la-seguridad-la-farmacocinetica-y-la-actividad-antitumoral-de-bc3195-en-pacientes-con-cancer-avanzado-o-metastasico 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06548672/a-study-to-assess-the-safety-pharmacokinetics-and-antitumor-activity-of-bc3195-in-patients-with-advanced-or-metastatic-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03842228/evaluacion-de-la-combinacion-de-los-farmacos-anticancerosos-copanlisib-olaparib-y-medi4736-durvalumab-en-pacientes-con-tumores-solidos-avanzados-con-mutaciones-seleccionadas 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03842228/testing-the-combination-of-the-anti-cancer-drugs-copanlisib-olaparib-and-medi4736-durvalumab-in-patients-with-advanced-solid-tumors-with-selected-mutations 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05882292/inhibidor-de-c-met-en-tumores-solidos-avanzados-con-alteraciones-en-el-gen-c-met 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05882292/c-met-inhibitor-in-advanced-solid-tumors-with-c-met-gene-aberration 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625593/un-estudio-de-primera-administracion-en-humanos-fih-de-bg-c137-un-conjugado-anticuerpo-farmaco-dirigido-al-receptor-2b-del-factor-de-crecimiento-de-fibroblastos-fgfr2b-en-participantes-con-tumores 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625593/a-first-in-human-fih-study-of-bg-c137-an-anti-fibroblast-growth-factor-receptor-2b-fgfr2b-antibody-drug-conjugate-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07583316/un-estudio-de-fase-i-el-primero-en-humanos-de-crpa1a2-un-activador-bispecifico-de-linfocitos-t-dirigido-a-mage-a1-hla-a-02-01-en-pacientes-con-tumores-solidos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583316/a-phase-1-first-in-human-study-of-crpa1a2-a-mage-a1-hla-a-02-01-bispecific-t-cell-engager-in-patients-with-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05877664/estudio-de-zg0895-hcl-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877664/study-of-zg0895-hcl-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06672523/un-estudio-para-evaluar-el-balance-de-masas-el-metabolismo-la-eliminacion-y-los-niveles-del-farmaco-14c-bms-986504-mrtx1719-en-participantes-con-tumores-solidos-avanzados-con-delecion-homocigotica 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06672523/a-study-to-evaluate-the-mass-balance-metabolism-elimination-and-drug-levels-of-14c-bms-986504-mrtx1719-in-participants-with-advanced-solid-tumors-with-homozygous-methylthioadenosine-phosphorylase 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05693844/terapia-celular-car-t-que-sobreexpresa-msln-y-se-utiliza-como-refuerzo-en-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05693844/pan-t-booster-co-expressing-msln-car-t-cell-therapy-in-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07600749/estudio-clinico-de-mk-4884-en-participantes-con-tumores-solidos-avanzados-o-metastasicos-mk-4884-001 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07600749/clinical-study-of-mk-4884-in-participants-with-advanced-or-metastatic-solid-tumors-mk-4884-001 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05142592/estudio-de-fase-i-iia-con-ipg7236-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05142592/phase1-2a-study-for-ipg7236-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06170294/terapia-con-celulas-t-modificadas-con-receptores-de-celulas-t-dirigidos-contra-mage-a4-en-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06170294/mage-a4-directed-tcr-t-in-the-treatment-amongst-subjects-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03843359/un-estudio-de-primera-administracion-en-humanos-ftih-de-gsk3745417-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03843359/a-first-time-in-human-ftih-study-of-gsk3745417-administered-to-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06639256/estudio-clinico-de-fase-1-2-de-hy07121-polvo-para-solucion-para-infusion-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06639256/phase-1-2-clinical-study-of-hy07121-powder-for-solution-for-infusion-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07083323/un-estudio-de-fase-i-ii-de-hy05350-en-tumores-solidos-avanzados-positivos-para-mesotelina-msln 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07083323/a-phase-i-ii-study-of-hy05350-in-mesothelin-msln-positive-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06724042/estudio-de-ism5939-en-pacientes-con-tumores-solidos-avanzados-y-o-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06724042/study-of-ism5939-in-patients-with-advanced-and-or-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05954091/oh2-administrado-mediante-inyeccion-intratumoral 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05954091/oh2-administered-by-intratumoral-injection 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06132217/un-estudio-de-simitinib-mas-sg001-en-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06132217/a-study-of-simmitinib-plus-sg001-in-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03440450/un-estudio-de-fase-i-de-escalada-de-dosis-de-ff-10832-para-el-tratamiento-de-tumores-solidos-incluidos-los-canceres-del-tracto-biliar 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03440450/a-phase-1-dose-escalation-study-of-ff-10832-for-treatment-of-solid-tumors-including-biliary-tract-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07106814/seguridad-y-eficacia-de-los-linfocitos-infiltrantes-tumorales-metabolicamente-potenciados-meta10-til-para-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07106814/safety-and-efficacy-of-metabolically-armed-tumor-lnfiltrating-lymphocytes-meta10-til-for-the-treatment-of-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05940116/un-estudio-clinico-de-fase-i-de-hs-20117-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05940116/a-phase-i-clinical-study-of-hs-20117-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07372625/un-estudio-para-investigar-los-efectos-de-multiples-dosis-de-rezatapopt-sobre-la-farmacocinetica-de-metformina-rosuvastatina-repaglinida-y-midazolam-en-pacientes-con-tumores-solidos-avanzados-que 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372625/a-study-to-investigate-the-effects-of-multiple-doses-of-rezatapopt-on-the-pharmacokinetics-of-metformin-rosuvastatin-repaglinide-and-midazolam-in-patients-with-advanced-solid-tumors-harboring-a-tp53 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270706/un-estudio-de-fase-i-de-pln-101095-en-adultos-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270706/a-phase-1-study-of-pln-101095-in-adults-with-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT02332668/un-estudio-de-pembrolizumab-mk-3475-en-participantes-pediatricos-con-un-tumor-solido-avanzado-o-linfoma-mk-3475-051-keynote-051 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT02332668/a-study-of-pembrolizumab-mk-3475-in-pediatric-participants-with-an-advanced-solid-tumor-or-lymphoma-mk-3475-051-keynote-051 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05038150/estudio-de-sgn1-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05038150/study-of-sgn1-in-patients-with-advanced-solid-tumor 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07181681/un-estudio-de-fase-i-en-humanos-con-bg-c0902-administrado-en-monoterapia-y-en-combinacion-con-otros-agentes-terapeuticos-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07181681/a-first-in-human-study-of-bg-c0902-alone-and-in-combination-with-other-therapeutic-agents-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06939270/celulas-hyposti-car-t-dirigidas-contra-cd73-axl-en-tumores-solidos-avanzados-metastasicos-positivos-para-cd73-axl 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06939270/cd73-axl-targeted-hyposti-car-t-cells-in-cd73-axl-positive-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06166888/un-estudio-de-ak131-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06166888/a-study-of-ak131-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07196644/un-estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-de-12-anos-o-mas-con-tumores-solidos-avanzados-localmente-o-metastasicos-que-presenten 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07196644/a-study-to-assess-adverse-events-and-change-in-disease-activity-in-participants-12-years-of-age-or-older-with-locally-advanced-or-metastatic-solid-tumors-that-harbor-met-amplification-receiving 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06929663/un-estudio-de-ak146d1-para-inyeccion-en-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06929663/a-study-of-ak146d1-for-injection-in-the-treatment-of-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589596/un-estudio-de-investigacion-de-bgb-58067-como-agente-unico-y-en-combinacion-con-agentes-antineoplasicos-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589596/an-investigational-study-of-bgb-58067-as-a-single-agent-and-in-combination-with-anticancer-agents-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06936735/un-estudio-de-fase-i-de-hs-20108-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06936735/a-phase-i-study-of-hs-20108-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04967833/un-estudio-de-las-celulas-til-gc101-en-tumores-solidos-avanzados-tr 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04967833/a-study-of-gc101-til-in-advanced-solid-tumors-tr 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05156203/estudio-de-seguridad-y-tolerabilidad-de-las-capsulas-de-t-1301-para-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05156203/safety-and-tolerability-study-for-t-1301-capsules-to-treat-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07582822/jh021-en-pacientes-con-tumores-solidos-avanzados-o-cpnp-con-mutacion-en-el-egfr 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07582822/jh021-in-patients-with-advanced-solid-tumors-or-egfr-mutant-nsclc 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06345482/un-estudio-de-mhb039a-en-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06345482/a-study-of-mhb039a-for-advanced-solid-tumor 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03682289/ceralasertib-azd6738-en-monoterapia-y-en-combinacion-con-olaparib-o-durvalumab-en-pacientes-con-tumores-solidos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03682289/ceralasertib-azd6738-alone-and-in-combination-with-olaparib-or-durvalumab-in-patients-with-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06509490/nkg2d-car-t-kd-025-en-el-tratamiento-de-tumores-solidos-avanzados-nkg2dl 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509490/nkg2d-car-t-kd-025-in-the-treatment-of-advanced-nkg2dl-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06928363/un-estudio-de-primera-administracion-en-humanos-de-ky-0301-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06928363/a-first-in-human-study-of-ky-0301-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05689853/estudio-de-ak119-en-combinacion-con-ak112-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05689853/study-of-ak119-combined-with-ak112-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184035/un-estudio-de-escalada-de-dosis-y-expansion-de-177lu-lu-sn201-en-participantes-con-cancer-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184035/a-dose-escalation-and-expansion-study-of-177lu-lu-sn201-in-participants-with-advanced-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07069062/un-estudio-clinico-de-fase-i-ii-en-humanos-con-hy0001a-para-inyeccion-en-participantes-adultos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07069062/a-phase-i-ii-human-study-of-hy0001a-for-injection-in-adult-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05366478/un-estudio-clinico-de-la-inyeccion-de-lm103-en-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05366478/a-clinical-study-of-lm103-injection-in-the-treatment-of-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05142423/un-estudio-de-ak109-en-combinacion-con-ak104-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05142423/a-study-of-ak109-combined-with-ak104-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03772561/estudio-de-fase-i-de-azd5363-olaparib-durvalumab-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03772561/phase-i-study-of-azd5363-olaparib-durvalumab-in-patients-with-advanced-or-metastatic-solid-tumor-malignancies 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05307705/un-estudio-de-loxo-783-en-pacientes-con-cancer-de-mama-otros-tumores-solidos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05307705/a-study-of-loxo-783-in-patients-with-breast-cancer-other-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04317105/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-copanlisib-al-tratamiento-inmunoterapeutico-habitual-nivolumab-con-o-sin-ipilimumab-en-pacientes-con-canceres-solidos-avanzados-que-presentan 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04317105/testing-the-addition-of-an-anti-cancer-drug-copanlisib-to-the-usual-immunotherapy-nivolumab-with-or-without-ipilimumab-in-patients-with-advanced-solid-cancers-that-have-changes-in-the-following-genes 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06208410/un-estudio-clinico-de-js105-en-combinacion-con-otras-terapias-antitumorales-en-pacientes-con-tumores-solidos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06208410/a-clinical-study-of-js105-in-combination-with-other-anti-tumor-therapies-in-patients-with-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07407504/gensci145-como-terapia-unica-o-en-combinacion-en-participantes-con-tumores-solidos-avanzados-localmente-o-metastasicos-con-mutacion-en-pik3ca 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07407504/gensci145-as-monotherapy-or-in-combination-therapy-in-participants-with-pik3ca-mutated-locally-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05538130/un-estudio-para-evaluar-el-medicamento-pf-07799544-tanto-en-monoterapia-como-en-combinacion-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05538130/a-study-to-learn-about-the-study-medicine-called-pf-07799544-as-monotherapy-or-in-combination-in-people-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07561554/estudio-de-fase-i-de-hsk42360-na-en-tumores-solidos-con-mutacion-braf-v600 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07561554/phase-i-study-of-hsk42360-na-in-solid-tumors-with-braf-v600-mutation 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03839342/binimetinib-y-encorafenib-para-el-tratamiento-de-tumores-solidos-avanzados-con-mutaciones-de-braf-que-no-son-v600e 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03839342/binimetinib-and-encorafenib-for-the-treatment-of-advanced-solid-tumors-with-non-v600e-braf-mutations 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02304809/estudio-de-fase-ii-para-evaluar-el-acceso-garantizado-a-vemurafenib-para-pacientes-con-tumores-que-presentan-alteraciones-genomicas-en-el-gen-braf 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02304809/phase-2-study-assessing-secured-access-to-vemurafenib-for-patients-with-tumors-harboring-braf-genomic-alterations 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06262919/vigilancia-de-los-resultados-del-uso-especial-de-tafinlar-mekinist 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06262919/special-drug-use-results-surveillance-of-tafinlar-mekinist 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244835/un-estudio-de-deg6498-en-participantes-con-tumores-solidos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244835/a-study-of-deg6498-in-participants-with-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06536400/estudio-de-fase-i-de-hsk42360-en-tumores-solidos-con-mutacion-braf-v600 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06536400/phase-i-study-of-hsk42360-in-solid-tumors-with-braf-v600-mutation 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06299839/pas-004-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06299839/pas-004-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06120283/bgb-43395-ya-sea-como-tratamiento-unico-o-como-parte-de-terapias-combinadas-en-participantes-con-cancer-de-mama-y-otros-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06120283/bgb-43395-alone-or-as-part-of-combination-therapies-in-participants-with-breast-cancer-and-other-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05150691/un-estudio-de-fase-1-2a-de-db-1303-bnt323-en-tumores-solidos-avanzados-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05150691/a-phase-1-2a-study-of-db-1303-bnt323-in-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245058/comprimidos-de-sph5030-en-pacientes-con-tumores-solidos-avanzados-her2-positivos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245058/sph5030-tablets-in-subjects-with-advanced-her2-positive-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06311214/terapia-personalizada-con-conjugados-anticuerpo-farmaco-basada-en-pruebas-de-arn-y-proteinas-para-el-tratamiento-de-tumores-solidos-avanzados-o-metastasicos-el-ensayo-de-deteccion-y-tratamiento-adc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06311214/personalized-antibody-drug-conjugate-therapy-based-on-rna-and-protein-testing-for-the-treatment-of-advanced-or-metastatic-solid-tumors-the-adc-match-screening-and-treatment-trial 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04389632/un-estudio-de-sigvotatug-vedotina-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04389632/a-study-of-sigvotatug-vedotin-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06504732/para-evaluar-iah0968-en-combinacion-con-capeox-en-el-cancer-gastrico-her2-positivo 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06504732/to-evaluate-iah0968-in-combination-with-capeox-in-her2-positive-gastric-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07142837/estudio-de-zg005-en-combinacion-con-gecacitinib-y-quimioterapia-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07142837/study-of-zg005-in-combination-with-gecacitinib-and-chemotherapy-for-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02453620/entinostat-nivolumab-e-ipilimumab-en-el-tratamiento-de-pacientes-con-tumores-solidos-metastasicos-o-que-no-pueden-ser-extirpados-quirurgicamente-o-con-cancer-de-mama-her2-negativo-localmente-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02453620/entinostat-nivolumab-and-ipilimumab-in-treating-patients-with-solid-tumors-that-are-metastatic-or-cannot-be-removed-by-surgery-or-locally-advanced-or-metastatic-her2-negative-breast-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04495296/un-ensayo-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-eficacia-preliminar-de-tst001-en-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495296/a-trial-to-evaluate-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-of-tst001-in-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05458219/un-estudio-de-fase-i-en-humanos-con-ibi343-en-sujetos-con-tumores-solidos-localmente-avanzados-irresecables-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05458219/a-first-in-human-study-of-ibi343-in-subjects-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06414733/vacuna-peptidica-her-2-para-celulas-b 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06414733/her-2-b-cell-peptide-vaccine 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04492488/un-estudio-de-mrg002-en-pacientes-con-tumores-solidos-avanzados-her2-positivos-y-cancer-gastrico-de-la-union-gastroesofagica-gej-localmente-avanzado-o-metastasico 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04492488/a-study-of-mrg002-in-patients-with-her2-positive-advanced-solid-tumors-and-locally-advanced-or-metastatic-gastric-gastroesophageal-junction-gej-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05768139/estudio-de-fase-i-en-humanos-de-tersolisib-stx-478-como-monoterapia-y-en-combinacion-con-otros-agentes-antineoplasicos-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768139/first-in-human-study-of-tersolisib-stx-478-as-monotherapy-and-in-combination-with-other-antineoplastic-agents-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04561362/estudio-bt8009-100-en-pacientes-con-tumores-malignos-avanzados-que-expresan-nectin-4 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04561362/study-bt8009-100-in-subjects-with-nectin-4-expressing-advanced-malignancies 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06993844/estudio-de-fase-1-2-de-etx-636-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06993844/phase-1-2-study-of-etx-636-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07514065/capsulas-de-tsl2109-en-pacientes-con-tumores-solidos-avanzados-seguridad-tolerabilidad-farmacocinetica-y-eficacia-preliminar 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07514065/tsl2109-capsules-in-advanced-solid-tumor-patients-safety-tolerability-pk-and-preliminary-efficacy 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05636215/un-estudio-de-fase-i-en-humanos-con-ibi354-en-sujetos-con-tumores-solidos-localmente-avanzados-irresecables-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05636215/a-first-in-human-study-of-ibi354-in-subjects-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05081609/un-estudio-para-investigar-la-seguridad-y-la-tolerabilidad-de-transcon-il-2-solo-o-en-combinacion-con-pembrolizumab-y-o-un-agonista-de-transcon-tlr7-8-u-otras-terapias-contra-el-cancer-en 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05081609/a-study-to-investigate-safety-and-tolerability-of-transcon-il-2-alone-or-in-combination-with-pembrolizumab-and-or-transcon-tlr7-8-agonist-or-other-anticancer-therapies-in-adult-participants-with 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07110883/un-estudio-clinico-de-sys6023-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07110883/a-clinical-study-of-sys6023-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06519110/neratinib-en-comprimidos-como-monoterapia-para-tumores-solidos-avanzados-con-mutaciones-en-her2 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06519110/neratinib-tablets-monotherapy-for-advanced-solid-tumors-with-her2-mutations 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02264678/dosis-crecientes-de-ceralasertib-en-combinacion-con-quimioterapia-y-o-nuevos-agentes-antineoplasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02264678/ascending-doses-of-ceralasertib-in-combination-with-chemotherapy-and-or-novel-anti-cancer-agents 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07287917/estudio-de-amxt-1501-y-dfmo-en-combinacion-con-terapias-estandar-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07287917/study-of-amxt-1501-and-dfmo-in-combination-with-standard-therapies-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06334432/estudio-de-seguridad-y-eficacia-de-nuv-1511-en-pacientes-adultos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06334432/safety-and-efficacy-study-of-nuv-1511-in-adult-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06827613/un-estudio-de-invikafusp-alfa-star0602-una-molecula-de-fusion-bifuncional-de-anticuerpos-que-se-dirige-selectivamente-al-receptor-de-celulas-t-tcr-en-combinacion-con-sacituzumab-govitecan-en 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06827613/a-study-of-invikafusp-alfa-star0602-a-selective-t-cell-receptor-tcr-targeting-bifunctional-antibody-fusion-molecule-in-combination-with-sacituzumab-govitecan-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06015048/un-ensayo-clinico-de-shr-a1811-en-combinacion-con-otras-terapias-antitumorales-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06015048/a-trial-of-shr-a1811-combined-with-other-antitumor-therapies-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714617/evaluar-bl-m17d1-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-que-expresan-o-presentan-mutaciones-en-her2 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06714617/evaluate-bl-m17d1-in-patients-w-her2-expressing-mutant-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06413615/un-estudio-de-fda022-bb05-en-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06413615/a-study-of-fda022-bb05-in-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06822998/hf50-en-tumores-solidos-avanzados-her2-positivos-y-con-baja-expresion-de-her2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06822998/hf50-in-her-2-positive-and-low-expression-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07424547/estudio-de-fase-i-de-sys6043-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07424547/phase-i-study-of-sys6043-in-patients-with-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05579366/rinatabart-sesutecan-rina-s-pro1184-gen1184-para-tumores-solidos-avanzados-gct1184-01-pro1184-001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05579366/rinatabart-sesutecan-rina-s-pro1184-gen1184-for-advanced-solid-tumors-gct1184-01-pro1184-001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06241456/ft825-ono-8250-una-terapia-car-t-anti-her2-lista-para-usar-con-o-sin-anticuerpos-monoclonales-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06241456/ft825-ono-8250-an-off-the-shelf-her2-car-t-with-or-without-monoclonal-antibodies-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05681650/celulas-car-t-hyposti-dirigidas-contra-her2-en-tumores-solidos-avanzados-her2-positivos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05681650/her2-targeted-hyposti-car-t-cells-in-her2-positive-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07524322/estudio-de-rgt-490-en-pacientes-con-tumores-solidos-avanzados-con-mutacion-en-pik3ca 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07524322/study-of-rgt-490-in-patients-with-pik3ca-mutated-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05872295/iks014-en-tumores-solidos-avanzados-que-expresan-her2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05872295/iks014-in-advanced-solid-tumors-that-express-her2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06669975/un-estudio-de-ap402-en-pacientes-con-tumores-solidos-her2-positivos-localmente-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06669975/a-study-of-ap402-in-her2-positive-patients-with-locally-or-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05957536/un-estudio-de-d3l-001-como-monoterapia-en-sujetos-con-tumores-solidos-avanzados-her2-positivos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05957536/a-study-of-d3l-001-as-monotherapy-in-subjects-with-her2-positive-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04872166/un-estudio-de-btx-a51-en-pacientes-con-tumores-solidos-avanzados-y-cancer-de-mama 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04872166/a-study-of-btx-a51-in-people-with-advanced-solid-tumor-and-breast-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861895/hf158k1-en-pacientes-con-tumores-solidos-avanzados-que-expresan-her-2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861895/hf158k1-in-patients-with-her-2-expressing-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06299124/un-estudio-de-fase-i-de-rgt-419b-en-pacientes-con-cancer-de-mama-avanzado-her2-negativo-y-receptor-hormonal-positivo-u-otros-tumores-solidos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06299124/a-phase-i-study-of-rgt-419b-in-patients-with-hr-positive-her2-negative-advanced-breast-cancer-or-other-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05564377/terapia-dirigida-basada-en-pruebas-geneticas-en-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados-o-localmente-avanzados-el-ensayo-de-cribado-combomatch 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05564377/targeted-therapy-directed-by-genetic-testing-in-treating-patients-with-locally-advanced-or-advanced-solid-tumors-the-combomatch-screening-trial 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07070232/un-estudio-clinico-para-evaluar-si-un-tratamiento-experimental-denominado-bnt326-es-seguro-y-potencialmente-beneficioso-cuando-se-utiliza-solo-o-en-combinacion-con-otros-tratamientos-experimentales 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07070232/a-clinical-study-to-test-if-an-investigational-treatment-called-bnt326-is-safe-and-potentially-beneficial-when-used-alone-or-in-combination-with-other-investigational-treatments-such-as-bnt327-for 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06084481/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-con-indicaciones-especificas-de-tumores-solidos-avanzados-que-reciben-abbv-400-por 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06084481/study-to-assess-adverse-events-and-change-in-disease-activity-in-adult-participants-with-select-advanced-solid-tumor-indications-receiving-intravenous-iv-abbv-400 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06239467/estudio-de-fase-i-en-humanos-de-oki-219-en-tumores-solidos-avanzados-y-cancer-de-mama-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06239467/first-in-human-study-of-oki-219-in-advanced-solid-tumors-and-advanced-breast-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07032298/un-estudio-de-fase-i-de-ssgj-612-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07032298/a-phase-i-study-of-ssgj-612-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05315700/estudio-de-oric-114-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-alteracion-en-egfr-o-her2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05315700/study-of-oric-114-in-patients-with-advanced-solid-tumors-harboring-an-egfr-or-her2-alteration 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07512583/estudios-clinicos-de-tqb2930-inyectable-para-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07512583/clinical-studies-of-tqb2930-injection-for-the-treatment-of-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05216432/estudio-de-fase-i-en-humanos-de-un-inhibidor-de-pi3k-selectivo-para-mutaciones-rly-2608-como-agente-unico-en-pacientes-con-tumores-solidos-avanzados-y-en-combinacion-con-terapia-endocrina-un 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05216432/first-in-human-study-of-mutant-selective-pi3k-inhibitor-rly-2608-as-a-single-agent-in-patients-with-advanced-solid-tumors-and-in-combination-with-endocrine-therapy-a-cdk4-6-or-cdk4-inhibitor-in 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06658951/inyeccion-de-celulas-car-t-anti-her2-en-pacientes-con-tumores-solidos-malignos-avanzados-her2-positivos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06658951/anti-her2-car-t-cell-injection-in-patients-with-her2-positive-advanced-malignant-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04152499/fase-i-ii-fih-adc-dirigido-a-trop2-tumores-solidos-avanzados-irresecables-metastasicos-refractarios-a-las-terapias-estandar-kl264-01 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04152499/phase-i-ii-fih-trop2-adc-advanced-unresectable-metastatic-solid-tumors-refractory-to-standard-therapies-kl264-01 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05804864/un-estudio-de-km501-en-pacientes-con-tumores-solidos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05804864/a-study-of-km501-in-patients-with-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06257264/un-estudio-para-examinar-la-seguridad-de-diferentes-dosis-de-bg-68501-administradas-a-participantes-con-tumores-en-estadio-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06257264/a-study-to-examine-the-safety-of-different-doses-of-bg-68501-given-to-participants-with-advanced-stage-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07230977/gensci139-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07230977/gensci139-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504445/estudio-clinico-sobre-la-eficacia-y-la-seguridad-de-car-dc-en-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07504445/clinical-study-on-the-efficacy-and-safety-of-car-dc-in-the-treatment-of-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05523947/ensayo-clinico-de-yh32367-en-pacientes-con-tumores-solidos-her2-positivos-localmente-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523947/clinical-trial-of-yh32367-in-patients-with-her2-positive-locally-advanced-or-metastatic-solid-tumor 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05898399/estudio-de-art6043-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-polka 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05898399/study-of-art6043-in-advanced-metastatic-solid-tumors-patients-polka 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07383506/un-estudio-de-un-inhibidor-selectivo-de-mutaciones-cgt6297-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07383506/a-study-of-mutant-selective-inhibitor-cgt6297-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05251714/cfi-402257-un-inhibidor-de-ttk-potente-y-selectivo-en-tumores-solidos-y-en-combinacion-con-fulvestrant-en-el-cancer-de-mama 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05251714/cfi-402257-a-potent-and-selective-ttk-inhibitor-in-solid-tumors-and-with-fulvestrant-in-breast-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06769425/hs-10502-tratamiento-combinado-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06769425/hs-10502-combination-treatment-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05311397/un-estudio-de-a166-en-pacientes-con-tumores-solidos-malignos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05311397/a-study-of-a166-in-patients-with-advanced-solid-malignant-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05933265/estudio-de-lp-184-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05933265/study-of-lp-184-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06376136/un-estudio-clinico-abierto-multicentrico-para-evaluar-la-seguridad-tolerabilidad-el-perfil-farmacocinetico-y-la-eficacia-clinica-inicial-de-bat-8010-para-inyeccion-en-combinacion-con-bat-1006-en-el 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06376136/a-multicenter-open-clinical-study-of-safety-tolerability-pharmacokinetic-profile-and-initial-clinical-efficacy-of-bat-8010-for-injection-combined-with-bat-1006-in-the-treatment-of-locally-advanced-or 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06512116/un-ensayo-clinico-de-la-inyeccion-sibp-a17-en-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06512116/a-clinical-trial-of-sibp-a17-injection-in-the-treatment-of-advanced-solid-tumor-patients 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646626/ssgj-705-mas-ssgj-612-quimioterapia-en-tumores-solidos-avanzados-her2-positivos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646626/ssgj-705-plus-ssgj-612-chemotherapy-in-advanced-her2-expressing-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05101096/estudio-de-sacituzumab-govitecan-sg-en-participantes-japoneses-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05101096/study-of-sacituzumab-govitecan-sg-in-japanese-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985655/estudio-para-evaluar-gtaexs617-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985655/study-to-assess-gtaexs617-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07122063/estudio-clinico-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-eficacia-preliminar-de-sys6045-en-pacientes-con-tumores-solidos-malignos-avanzados-her2-positivos-que-expresen-o 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07122063/clinical-study-to-evaluate-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-of-sys6045-in-patients-with-her2-positive-expressing-or-mutated-advanced-malignant-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05940896/rc48-adc-en-combinacion-con-radioterapia-en-el-tratamiento-de-tumores-solidos-localmente-avanzados-con-expresion-de-her2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05940896/rc48-adc-combined-with-radiotherapy-in-the-treatment-of-locally-advanced-solid-tumors-with-her2-expression 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07601334/seguridad-y-actividad-de-hf50-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07601334/safety-and-activity-of-hf50-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05143970/un-estudio-de-fase-i-el-primero-en-humanos-del-anti-cd73-iph5301-administrado-solo-o-en-combinacion-con-quimioterapia-y-trastuzumab-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05143970/a-phase-1-first-in-human-study-of-the-anti-cd73-iph5301-alone-or-in-combination-with-chemotherapy-and-trastuzumab-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05275777/un-estudio-de-fase-ib-para-evaluar-la-seguridad-seguido-de-un-estudio-de-fase-ii-de-adg106-en-combinacion-con-quimioterapia-neoadyuvante-en-cancer-de-mama-her2-negativo 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05275777/a-phase-ib-safety-lead-in-followed-by-phase-ii-trial-of-adg106-in-combination-with-neoadjuvant-chemotherapy-in-her2-negative-breast-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06719362/un-ensayo-clinico-para-evaluar-la-seguridad-la-tolerabilidad-y-la-eficacia-clinica-de-la-monoterapia-con-m3t01-y-en-combinacion-con-pembrolizumab-y-otras-terapias-sistemicas 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06719362/a-clinical-trial-to-evaluate-the-safety-tolerability-and-clinical-efficacy-of-m3t01-monotherapy-and-in-combination-with-pembrolizumab-and-other-systemic-therapies 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06431243/un-estudio-clinico-de-purinostat-mesilato-para-inyeccion-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06431243/a-clinical-study-of-purinostat-mesylate-for-injection-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06003231/un-estudio-de-disitamab-vedotina-en-tumores-solidos-previamente-tratados-que-expresan-her2 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06003231/a-study-of-disitamab-vedotin-in-previously-treated-solid-tumors-that-express-her2 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04639219/un-estudio-de-t-dxd-para-el-tratamiento-de-tumores-solidos-que-presentan-mutaciones-activadoras-de-her2 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04639219/a-study-of-t-dxd-for-the-treatment-of-solid-tumors-harboring-her2-activating-mutations 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04282031/un-estudio-de-bpi-1178-en-pacientes-con-tumor-solido-avanzado-y-cancer-de-mama-hr-her2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04282031/a-study-of-bpi-1178-in-patients-with-advanced-solid-tumor-and-hr-her2-breast-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998407/orion-1-estudio-de-avzo-023-como-agente-unico-y-en-combinacion-con-avzo-021-y-o-terapia-endocrina-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998407/orion-1-study-of-avzo-023-as-a-single-agent-and-in-combination-with-avzo-021-and-or-endocrine-therapy-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06644300/estudio-de-bm230-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06644300/study-of-bm230-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04606446/estudio-de-pf-07248144-en-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04606446/study-of-pf-07248144-in-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06027983/celulas-t-con-receptores-quimericos-y-trastuzumab-en-cancer-de-mama-avanzado-her2-y-otros-tumores-solidos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06027983/chimeric-receptor-t-cells-with-trastuzumab-in-her2-advanced-breast-cancer-and-other-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05593094/un-ensayo-de-fase-i-con-capsulas-entericas-de-zn-a-1041-o-en-combinacion-en-participantes-con-tumores-solidos-avanzados-her2-positivos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05593094/a-phase-1-trial-of-zn-a-1041-enteric-capsules-or-combination-in-participants-with-human-epidermal-growth-factor-receptor-2-her2-positive-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616766/un-estudio-de-fase-1-2-abierto-multicentrico-de-investigacion-del-investigador-fih-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-de-yh42946 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06616766/a-phase-1-2-open-label-multicenter-fih-study-to-evaluate-safety-tolerability-pk-and-anti-tumor-activity-of-yh42946 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04294628/evaluacion-de-los-efectos-biologicos-de-ds-8201a-en-pacientes-con-cancer-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04294628/testing-the-biological-effects-of-ds-8201a-on-patients-with-advanced-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06157892/un-estudio-de-disitamab-vedotina-con-otros-farmacos-antineoplasicos-en-tumores-solidos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06157892/a-study-of-disitamab-vedotin-with-other-anticancer-drugs-in-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05627960/estudio-de-fase-i-el-primero-en-humanos-del-anticuerpo-anti-progranulina-gp88-ag01-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05627960/first-in-human-phase-1-study-of-ag01-anti-progranulin-gp88-antibody-in-advanced-solid-tumor-malignancies 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04997993/leflunomida-en-pacientes-con-tumores-solidos-avanzados-con-alteraciones-en-el-gen-pten-y-cancer-de-mama-her2-negativo 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04997993/leflunomide-in-patients-with-pten-altered-advanced-solid-malignancies-and-her2-negative-breast-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06950086/estudio-de-las-tabletas-de-tyk-00540-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06950086/study-of-tyk-00540-tablets-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05423977/estudio-de-zv0203-en-pacientes-con-tumores-solidos-avanzados-her2-positivos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05423977/study-of-zv0203-in-patients-with-her2-positive-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06244485/un-estudio-de-valemetostat-tosilato-en-combinacion-con-anticuerpos-farmaco-conjugados-adc-dirigidos-a-dxd-en-sujetos-con-tumores-solidos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244485/a-study-of-valemetostat-tosylate-in-combination-with-dxd-adcs-in-subjects-with-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05720117/un-estudio-de-pyx-201-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05720117/a-study-of-pyx-201-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06101082/un-estudio-clinico-que-evalua-la-seguridad-y-la-eficacia-de-la-inyeccion-de-celulas-car-t-anti-her2-en-pacientes-con-tumores-solidos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06101082/a-clinical-study-evaluating-the-safety-and-efficacy-of-anti-her2-car-t-cells-injection-in-patients-with-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07038369/un-estudio-de-fase-i-de-atv-1601-en-pacientes-con-cancer-avanzado-que-presentan-mutaciones-e17k-en-el-gen-akt1 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038369/a-phase-1-study-of-atv-1601-in-patients-with-advanced-cancer-that-have-akt1-e17k-mutations 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07361562/un-estudio-de-un-inhibidor-selectivo-de-erbb2-cgt4255-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361562/a-study-of-a-selective-erbb2-inhibitor-cgt4255-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523529/celulas-car-t-dirigidas-a-dos-dianas-y-guiadas-por-biomarcadores-para-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523529/biomarker-guided-dual-target-car-t-cells-for-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907043/un-estudio-de-un-inhibidor-selectivo-de-parp1-eik1004-imp1707-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907043/a-study-of-parp1-selective-inhibitor-eik1004-imp1707-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07612891/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-preliminar-de-inv-6452-en-pacientes-adultos-con-cancer-de-mama-avanzado-o-metastasico-receptor 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07612891/a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-preliminary-antitumor-activity-of-inv-6452-in-adult-patients-with-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06188520/un-estudio-de-fase-i-de-escalada-de-dosis-y-expansion-para-evaluar-la-seguridad-y-la-tolerabilidad-de-azd8421-en-monoterapia-o-en-combinacion-en-participantes-con-tumores-solidos-avanzados-o 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06188520/a-first-in-human-dose-escalation-and-expansion-study-to-evaluate-the-safety-and-tolerability-of-azd8421-alone-or-in-combination-in-participants-with-selected-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06112041/estudio-clinico-prospectivo-de-terapia-prag-de-precision-en-pacientes-ancianos-con-tumores-solidos-malignos-avanzados-prag9-0 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06112041/the-prospective-clinical-study-of-precision-prag-therapy-in-elderly-patients-with-advanced-solid-malignant-tumors-prag9-0 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07109726/un-ensayo-de-fase-i-ii-de-ter-2013-en-pacientes-con-tumores-solidos-que-presentan-alteraciones-en-la-via-akt-pi3k-pten 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07109726/a-phase-1-2-trial-of-ter-2013-in-patients-with-solid-tumors-harboring-akt-pi3k-pten-pathway-alterations 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05417594/estudio-de-azd9574-como-monoterapia-y-en-combinacion-con-agentes-antineoplasicos-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05417594/study-of-azd9574-as-monotherapy-and-in-combination-with-anti-cancer-agents-in-participants-with-advanced-solid-malignancies 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06784193/estudio-de-fase-i-de-op-3136-en-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06784193/phase-1-study-of-op-3136-in-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07287995/un-estudio-de-asp2998-administrado-solo-y-en-combinacion-con-terapias-estandar-en-pacientes-con-tumores-solidos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07287995/a-study-of-asp2998-given-by-itself-and-given-with-standard-therapies-in-people-with-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07309770/trastuzumab-rezetecan-en-tumores-solidos-avanzados-refractarios-a-las-terapias-estandar 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07309770/trastuzumab-rezetecan-in-advanced-solid-tumors-refractory-to-standard-therapies 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05765851/un-estudio-de-la-terapia-combinada-con-ds-1103a-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05765851/a-study-of-ds-1103a-combination-therapy-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06172478/un-estudio-de-her3-dxd-en-sujetos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06172478/a-study-of-her3-dxd-in-subjects-with-locally-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04913285/un-estudio-para-evaluar-kin-2787-en-participantes-con-tumores-solidos-braf-y-o-nras-positivos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04913285/a-study-to-evaluate-kin-2787-in-participants-with-braf-and-or-nras-mutation-positive-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06484556/terapia-celular-con-celulas-t-modificadas-geneticamente-para-expresar-el-receptor-de-celulas-t-dirigida-a-las-mutaciones-de-kras-en-el-tratamiento-de-sujetos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484556/t-cell-receptor-gene-engineered-t-cell-therapy-targeting-kras-mutations-in-the-treatment-of-subjects-with-advanced-solid-tumor 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07094113/amg-410-en-monoterapia-y-en-combinacion-con-otros-farmacos-en-participantes-con-tumores-solidos-avanzados-o-metastasicos-con-alteraciones-en-el-gen-kras 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07094113/amg-410-alone-and-in-combination-with-other-agents-in-participants-with-kras-altered-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03600883/un-estudio-de-fase-1-2-que-evalua-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-eficacia-de-sotorasib-amg-510-en-sujetos-con-tumores-solidos-que-presentan-una-mutacion-especifica-en-el-gen 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03600883/a-phase-1-2-study-evaluating-the-safety-tolerability-pk-and-efficacy-of-sotorasib-amg-510-in-subjects-with-solid-tumors-with-a-specific-kras-mutation-codebreak-100 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05367778/estudio-de-fase-1-2-de-hs-10370-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05367778/phase-1-2-study-of-hs-10370-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05631899/vacuna-car-dc-e-inhibidores-de-puntos-de-control-inmunitario-en-tumores-solidos-avanzados-localmente-o-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05631899/car-dc-vaccine-and-icis-in-local-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594874/un-estudio-de-fase-ib-de-hs-10370-en-combinacion-con-otras-terapias-antineoplasicas-en-participantes-con-tumores-solidos-avanzados-con-mutacion-kras-g12c 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594874/a-phase-ib-study-of-hs-10370-in-addition-to-other-anti-cancer-therapies-in-participants-with-kras-g12c-mutation-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04185883/actividad-de-sotorasib-en-sujetos-con-tumores-solidos-avanzados-con-mutacion-kras-p-g12c-codebreak-101 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04185883/sotorasib-activity-in-subjects-with-advanced-solid-tumors-with-kras-p-g12c-mutation-codebreak-101 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06478251/terapia-celular-con-celulas-t-modificadas-geneticamente-para-expresar-el-receptor-de-celulas-t-dirigida-a-las-mutaciones-de-kras-en-el-tratamiento-de-sujetos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06478251/t-cell-receptor-gene-engineered-t-cell-therapy-targeting-kras-mutations-in-the-treatment-of-subjects-with-advanced-solid-tumor 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06520488/un-estudio-de-hrs-4642-en-combinacion-con-agentes-antineoplasicos-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06520488/a-study-of-hrs-4642-in-combination-with-antineoplastic-agents-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06619587/un-estudio-para-evaluar-la-seguridad-la-farmacocinetica-y-la-actividad-de-gdc-7035-como-agente-unico-y-en-combinacion-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06619587/a-study-to-evaluate-safety-pharmacokinetics-and-activity-of-gdc-7035-as-a-single-agent-and-in-combination-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06797336/un-estudio-de-pt0253-en-participantes-con-tumores-solidos-avanzados-con-mutacion-kras-g12d 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06797336/a-study-of-pt0253-in-participants-with-kras-g12d-mutated-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04973163/un-estudio-para-evaluar-diferentes-dosis-de-bi-1823911-solo-y-en-combinacion-con-otros-medicamentos-en-pacientes-con-diferentes-tipos-de-cancer-avanzado-con-mutacion-en-el-gen-kras 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04973163/a-study-to-test-different-doses-of-bi-1823911-alone-and-combined-with-other-medicines-in-people-with-different-types-of-advanced-cancer-with-kras-mutation 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05327010/evaluacion-de-la-combinacion-de-los-farmacos-antineoplasicos-zen003694-zen-3694-y-talazoparib-en-pacientes-con-tumores-solidos-avanzados-ensayo-combet 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05327010/testing-the-combination-of-the-anti-cancer-drugs-zen003694-zen-3694-and-talazoparib-in-patients-with-advanced-solid-tumors-the-combet-trial 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06667544/un-estudio-de-rnk08954-en-sujetos-con-tumores-solidos-avanzados-con-mutacion-kras-g12d-del-gen-kirsten-rat-sarcoma 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06667544/a-study-of-rnk08954-in-subjects-with-advanced-solid-tumors-with-kras-kirsten-rat-sarcoma-g12d-mutation 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07650357/un-estudio-de-clsp-5282-en-pacientes-adultos-con-tumores-solidos-positivos-para-hla-a-03-01-sentinel-101 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07650357/a-study-of-clsp-5282-in-hla-a-03-01-positive-adult-patients-with-solid-tumors-sentinel-101 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05785741/un-estudio-de-db-1310-en-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05785741/a-study-of-db-1310-in-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07615413/estudio-de-fase-i-de-hs-10541-como-monoterapia-o-en-combinacion-con-otras-terapias-antineoplasicas-en-pacientes-con-tumores-solidos-avanzados-con-mutacion-kras-g12c 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07615413/phase-1-study-of-hs-10541-as-monotherapy-or-in-combination-with-other-anti-cancer-therapies-in-patients-with-kras-g12c-mutation-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07252479/evaluacion-del-tratamiento-con-un-inhibidor-de-ras-en-participantes-con-tumores-solidos-avanzados-o-metastasicos-que-presenten-mutaciones-en-ras 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07252479/evaluation-of-ras-inhibitor-treatment-in-participants-with-advanced-or-metastatic-solid-tumors-harboring-ras-mutations 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06435455/gh21-en-combinacion-con-d-1553-en-tumores-solidos-avanzados-con-mutacion-kras-g12c 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06435455/gh21-combined-with-d-1553-in-kras-g12c-mutant-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959615/un-estudio-de-fase-i-iia-de-jab-23e73-en-pacientes-con-tumores-solidos-avanzados-que-presentan-alteraciones-en-el-gen-kras 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959615/a-phase-i-iia-study-of-jab-23e73-in-patients-with-advanced-solid-tumors-harboring-kras-gene-alteration 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06166836/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-d-1553-en-combinacion-con-in10018-en-tumores-solidos-con-mutacion-kras-g12c 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06166836/a-study-to-evaluate-the-safety-and-efficacy-of-d-1553-combined-with-in10018-in-kras-g12c-mutant-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06008288/un-estudio-de-fase-ii-que-evalua-la-monoterapia-con-jab-21822-en-pacientes-adultos-con-cancer-de-pancreas-y-otros-tumores-solidos-que-presentan-la-mutacion-kras-p-g12c 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008288/a-phase-ii-study-evaluating-jab-21822-monotherapy-in-adult-patients-with-pancreatic-cancer-and-other-solid-tumors-harboring-the-kras-p-g12c-mutation 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484790/terapia-celular-con-celulas-t-modificadas-geneticamente-para-expresar-el-receptor-de-celulas-t-dirigida-a-las-mutaciones-de-kras-en-el-tratamiento-de-sujetos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484790/t-cell-receptor-gene-engineered-t-cell-therapy-targeting-kras-mutations-in-the-treatment-of-subjects-with-advanced-solid-tumor 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243354/estudio-de-fase-i-ii-de-hyp-2090ptsa-en-pacientes-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243354/phase-1-2-study-of-hyp-2090ptsa-in-patients-with-advanced-solid-tumors-harboring-kras-mutation 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06162221/estudio-de-inhibidores-de-ras-on-en-pacientes-con-cancer-de-pulmon-no-microcitico-cpnm-avanzado-con-mutacion-en-el-gen-ras 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06162221/study-of-ras-on-inhibitors-in-patients-with-advanced-ras-mutated-nsclc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03065387/neratinib-y-everolimus-palbociclib-o-trametinib-en-el-tratamiento-de-participantes-con-tumores-solidos-avanzados-o-metastasicos-refractarios-y-con-mutacion-amplificacion-de-egfr-mutacion 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03065387/neratinib-and-everolimus-palbociclib-or-trametinib-in-treating-participants-with-refractory-and-advanced-or-metastatic-solid-tumors-with-egfr-mutation-amplification-her2-mutation-amplification-or 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134998/estudio-de-fase-i-de-hrs-6093-en-participantes-con-tumores-solidos-avanzados-que-presentan-mutaciones-kras-g12d 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134998/phase-i-study-of-hrs-6093-in-participants-with-advanced-solid-tumors-harboring-kras-g12d-mutations 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07021898/un-estudio-de-eras-4001-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07021898/a-study-of-eras-4001-in-patients-with-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06944457/ensayo-clinico-para-evaluar-la-seguridad-la-tolerabilidad-y-la-farmacocinetica-de-mpd-1-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06944457/clinical-trial-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-mpd-1-in-patients-with-advanced-solid-tumor 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06096974/inhibidor-pan-ras-yl-17231-en-pacientes-con-tumores-solidos-avanzados-que-presentan-mutaciones-en-kras-hras-o-nras 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06096974/pan-ras-inhibitor-yl-17231-in-patients-with-advanced-solid-tumors-harboring-mutations-in-kras-hras-or-nras 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875820/ensayo-de-fase-i-con-defactinib-y-vs-6766 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03875820/phase-i-trial-of-defactinib-and-vs-6766 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05410145/un-estudio-de-la-monoterapia-con-d3s-001-o-la-terapia-combinada-en-sujetos-con-tumores-solidos-avanzados-con-una-mutacion-kras-p-g12c 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05410145/a-study-of-d3s-001-monotherapy-or-combination-therapy-in-subjects-with-advanced-solid-tumors-with-a-kras-p-g12c-mutation 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05009329/un-estudio-de-jab-21822-en-pacientes-adultos-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras-p-g12c-en-china 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009329/a-study-of-jab-21822-in-adult-patients-with-advanced-solid-tumors-harboring-kras-p-g12c-mutation-in-china 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06804824/un-estudio-de-fase-inicial-en-humanos-fih-para-evaluar-la-seguridad-y-la-tolerabilidad-de-vvd-159642-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06804824/a-first-in-human-fih-study-to-evaluate-the-safety-and-tolerability-of-vvd-159642-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07342738/terapia-con-celulas-t-modificadas-con-receptores-de-celulas-t-tcr-para-tumores-solidos-avanzados-con-mutacion-en-el-gen-kras 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07342738/tcr-t-cell-therapy-for-kras-mutation-in-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403436/un-estudio-que-evalua-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-eficacia-de-tt125-802-en-sujetos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403436/a-study-evaluating-the-safety-tolerability-pharmacokinetics-and-efficacy-of-tt125-802-in-subjects-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06970132/estudio-de-sy-5933-mas-ct-707-en-tumores-solidos-avanzados-con-mutacion-kras-p-g12c 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06970132/study-of-sy-5933-plus-ct-707-in-advanced-solid-tumors-with-kras-p-g12c-mutation 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06385678/un-estudio-de-hrs-4642-en-pacientes-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras-g12d 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06385678/a-study-of-hrs-4642-in-patients-with-advanced-solid-tumors-harboring-kras-g12d-mutation 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07417189/un-estudio-de-fase-i-ii-de-absk141-en-pacientes-con-tumores-solidos-avanzados-absk141-101 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07417189/a-phase-i-ii-study-of-absk141-in-patients-with-advanced-solid-tumors-absk141-101 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179160/un-estudio-para-evaluar-incb161734-en-participantes-con-tumores-solidos-avanzados-o-metastasicos-con-mutacion-kras-g12d 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179160/a-study-to-evaluate-incb161734-in-participants-with-advanced-or-metastatic-solid-tumors-with-kras-g12d-mutation 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05382559/un-estudio-de-asp3082-en-adultos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05382559/a-study-of-asp3082-in-adults-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585320/un-estudio-de-fase-1-2a-de-imm-1-104-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05585320/a-phase-1-2a-study-of-imm-1-104-in-participants-with-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05933668/terapia-con-celulas-t-modificadas-con-tcr-especifico-para-kras-g12v-mutado-en-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05933668/mutant-kras-g12v-specific-tcr-transduced-t-cell-therapy-for-advanced-solid-tumor 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06715124/qtx3544-en-pacientes-con-tumores-solidos-avanzados-con-mutaciones-kras-g12v 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06715124/qtx3544-in-patients-with-advanced-solid-tumors-with-kras-g12v-mutations 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06364696/un-estudio-para-determinar-una-dosis-adecuada-de-asp4396-en-adultos-con-tumores-solidos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06364696/a-study-to-find-a-suitable-dose-of-asp4396-in-adults-with-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949761/un-estudio-clinico-para-evaluar-la-seguridad-la-tolerabilidad-y-la-eficacia-de-qlc1101-en-combinacion-con-otras-terapias-en-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados-que-presentan-una 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949761/a-clinical-study-to-evaluate-the-safety-tolerability-and-efficacy-of-qlc1101-in-combination-with-other-therapies-in-the-treatment-of-patients-with-advanced-solid-tumors-harboring-a-kras-g12d-mutation 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05638295/evaluacion-del-uso-de-amg-510-sotorasib-y-panitumumab-como-tratamiento-dirigido-para-canceres-de-tumores-solidos-con-mutacion-kras-g12c-ensayo-clinico-combomatch 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05638295/testing-the-use-of-amg-510-sotorasib-and-panitumumab-as-a-targeted-treatment-for-kras-g12c-mutant-solid-tumor-cancers-a-combomatch-treatment-trial 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07247110/un-estudio-clinico-de-mk-4716-en-pacientes-con-determinados-tumores-solidos-mk-4716-001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07247110/a-clinical-study-of-mk-4716-in-people-with-certain-solid-tumors-mk-4716-001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06947811/un-estudio-de-almonertinib-en-combinacion-con-palbociclib-en-pacientes-con-tumores-solidos-avanzados-que-presentan-mutaciones-en-el-gen-kras 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06947811/a-study-of-almonertinib-combined-with-palbociclib-in-patients-with-advanced-solid-tumors-harboring-kras-mutations 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05438667/terapia-con-celulas-t-modificadas-con-receptores-de-celulas-t-tcr-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05438667/tcr-t-cell-therapy-on-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07456046/un-estudio-de-fase-i-de-d3s-003-como-monoterapia-en-participantes-con-tumores-solidos-avanzados-con-una-mutacion-kras-p-g12d 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07456046/a-phase-1-study-of-d3s-003-as-monotherapy-in-participants-with-advanced-solid-tumors-with-a-kras-p-g12d-mutation 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT02079740/trametinib-y-navitoclax-en-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02079740/trametinib-and-navitoclax-in-treating-patients-with-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06956261/nw-301-terapia-con-celulas-t-modificadas-con-receptores-quimericos-tcr-t-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06956261/nw-301-tcr-t-in-patients-with-advanced-solid-tumor 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05887492/estudio-de-tng260-y-un-anticuerpo-anti-pd-en-tumores-solidos-con-mutacion-en-stk11 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05887492/study-of-tng260-and-an-anti-pd-antibody-in-stk11-mutated-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07474168/terapia-celular-con-receptores-de-celulas-t-modificados-geneticamente-y-receptores-de-tgf-dominantes-negativos-dirigida-a-las-mutaciones-de-kras-en-el-tratamiento-de-sujetos-con-tumores-solidos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07474168/t-cell-receptor-gene-engineered-and-dominant-negative-tgf-receptor-t-cell-therapy-targeting-kras-mutations-in-the-treatment-of-subjects-with-advanced-solid-tumor 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03785249/estudio-de-fase-1-2-de-mrtx849-en-pacientes-con-cancer-que-presentan-una-mutacion-kras-g12c-krystal-1 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03785249/phase-1-2-study-of-mrtx849-in-patients-with-cancer-having-a-kras-g12c-mutation-krystal-1 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07441174/in10018-en-combinacion-con-rnk08954-para-el-tratamiento-de-tumores-solidos-avanzados-localmente-o-metastasicos-con-mutacion-krasg12d 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07441174/in10018-in-combination-with-rnk08954-for-the-treatment-of-krasg12d-mutation-positive-locally-advanced-or-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06963398/un-estudio-de-hs-10529-en-pacientes-con-tumores-solidos-avanzados-y-mutacion-kras-g12d 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06963398/a-study-of-hs-10529-in-kras-g12d-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05533463/estudio-de-fase-i-de-hrs-4642-en-pacientes-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras-g12d 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05533463/phase-i-study-of-hrs-4642-in-patients-with-advanced-solid-tumors-harboring-kras-g12d-mutation 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05067283/un-estudio-de-calderasib-mk-1084-en-tumores-solidos-avanzados-con-mutacion-de-kras-mk-1084-001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05067283/a-study-of-calderasib-mk-1084-in-kras-mutant-advanced-solid-tumors-mk-1084-001 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500676/un-estudio-de-gfh375-en-pacientes-con-tumores-solidos-avanzados-con-mutaciones-kras-g12d 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500676/a-study-of-gfh375-in-patients-with-advanced-solid-tumors-with-kras-g12d-mutations 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06874335/un-estudio-de-fase-i-de-bhv-1530-en-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06874335/a-phase-1-study-of-bhv-1530-in-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05544552/seguridad-y-actividad-antitumoral-preliminar-de-tyra-300-en-carcinoma-urotelial-avanzado-y-otros-tumores-solidos-con-alteraciones-en-el-gen-fgfr3 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05544552/safety-and-preliminary-anti-tumor-activity-of-tyra-300-in-advanced-urothelial-carcinoma-and-other-solid-tumors-with-fgfr3-gene-alterations 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06915753/seguridad-y-actividad-antitumoral-preliminar-de-tyra-430-en-carcinoma-hepatocelular-avanzado-y-otros-tumores-solidos-con-alteraciones-activadoras-de-la-via-fgf-fgfr 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06915753/safety-and-preliminary-anti-tumor-activity-of-tyra-430-in-advanced-hepatocellular-carcinoma-and-other-solid-tumors-with-activating-fgf-fgfr-pathway-aberrations 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05614739/forager-1-un-estudio-de-loxo-435-ly3866288-en-participantes-con-cancer-que-presentan-una-alteracion-en-un-gen-denominado-fgfr3 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05614739/forager-1-a-study-of-loxo-435-ly3866288-in-participants-with-cancer-with-a-change-in-a-gene-called-fgfr3 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06302621/pemigatinib-afatinib-en-tumores-solidos-avanzados-refractarios 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06302621/pemigatinib-afatinib-in-advanced-refractory-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06777316/un-estudio-de-un-inhibidor-de-fgfr2-3-cgt4859-en-pacientes-con-colangiocarcinoma-y-otros-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06777316/a-study-of-an-fgfr2-3-inhibitor-cgt4859-in-patients-with-cholangiocarcinoma-and-other-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06160752/seguridad-y-actividad-antitumoral-de-tyra-200-en-el-colangiocarcinoma-avanzado-con-alteraciones-activadoras-del-gen-fgfr2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06160752/safety-and-anti-tumor-activity-of-tyra-200-in-advanced-cholangiocarcinoma-with-activating-fgfr2-gene-alterations 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359820/un-estudio-de-lirafugratinib-en-tumores-solidos-no-derivados-del-colangiocarcinoma-con-fusion-o-reordenamiento-de-fgfr2 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359820/a-study-of-lirafugratinib-in-non-cca-solid-tumors-with-fgfr2-fusion-or-rearrangement 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06656390/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-la-farmacocinetica-pk-y-la-actividad-antitumoral-de-alk201-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06656390/a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-pk-and-antitumor-activity-of-alk201-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05653869/un-estudio-de-aps03118-en-tumores-solidos-avanzados-que-presentan-mutaciones-o-fusiones-en-el-gen-ret 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05653869/a-study-of-aps03118-in-advanced-solid-tumors-harboring-ret-mutations-or-fusions 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05451602/hec169096-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05451602/hec169096-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07252661/estudio-de-acc-1898-en-participantes-adultos-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07252661/study-of-acc-1898-in-adult-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04280081/un-estudio-de-selpercatinib-ly3527723-en-participantes-con-tumores-solidos-avanzados-incluidos-los-tumores-solidos-con-fusion-de-ret-el-cancer-de-tiroides-medular-y-otros-tumores-con-activacion-de-ret 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04280081/a-study-of-selpercatinib-ly3527723-in-participants-with-advanced-solid-tumors-including-ret-fusion-positive-solid-tumors-medullary-thyroid-cancer-and-other-tumors-with-ret-activation 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04683250/estudio-del-inhibidor-de-ret-tas0953-hm06-en-pacientes-con-tumores-solidos-avanzados-con-alteraciones-en-el-gen-ret 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04683250/study-of-ret-inhibitor-tas0953-hm06-in-patients-with-advanced-solid-tumors-with-ret-gene-abnormalities 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06169579/un-estudio-abierto-de-fase-i-para-determinar-la-dosis-maxima-tolerada-de-nd-003-en-pacientes-con-canceres-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06169579/an-open-label-phase-1-study-to-determine-the-maximum-tolerated-dose-of-nd-003-in-patients-with-advanced-solid-cancers 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05265091/un-estudio-de-kl590586-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05265091/a-study-of-kl590586-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02029001/adaptacion-del-tratamiento-a-las-alteraciones-moleculares-del-tumor-en-pacientes-con-tumores-solidos-avanzados-myownspecifictreatment 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT02029001/adapting-treatment-to-the-tumor-molecular-alterations-for-patients-with-advanced-solid-tumors-myownspecifictreatment 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04320888/selpercatinib-para-el-tratamiento-de-tumores-solidos-avanzados-linfomas-u-otros-trastornos-histiociticos-con-alteraciones-activadoras-del-gen-ret-un-ensayo-de-tratamiento-pediatrico-match 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04320888/selpercatinib-for-the-treatment-of-advanced-solid-tumors-lymphomas-or-histiocytic-disorders-with-activating-ret-gene-alterations-a-pediatric-match-treatment-trial 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03155620/terapia-dirigida-basada-en-pruebas-geneticas-para-el-tratamiento-de-pacientes-pediatricos-con-tumores-solidos-avanzados-recurrentes-o-refractarios-linfomas-no-hodgkin-u-otros-trastornos-histiociticos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03155620/targeted-therapy-directed-by-genetic-testing-in-treating-pediatric-patients-with-relapsed-or-refractory-advanced-solid-tumors-non-hodgkin-lymphomas-or-histiocytic-disorders-the-pediatric-match 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03556228/vmd-928-en-monoterapia-y-en-combinacion-con-pembrolizumab-para-el-tratamiento-de-tumores-solidos-o-linfomas-con-sobreexpresion-de-trka 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03556228/vmd-928-monotherapy-and-in-combination-with-pembrolizumab-to-treat-trka-overexpression-driven-solid-tumors-or-lymphoma 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04606381/un-estudio-sobre-la-administracion-subcutanea-de-amivantamab-para-el-tratamiento-de-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04606381/a-study-of-amivantamab-subcutaneous-sc-administration-for-the-treatment-of-advanced-solid-malignancies 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05525858/estudio-kpmng-sobre-terapia-guiada-por-el-perfilado-molecular-basada-en-alteraciones-genomicas-en-tumores-solidos-avanzados-ii 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05525858/kpmng-study-of-molecular-profiling-guided-therapy-based-on-genomic-alterations-in-advanced-solid-tumors-ii 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03767075/un-ensayo-modular-multi-cestas-para-mejorar-la-medicina-personalizada-en-pacientes-con-cancer-ensayo-de-multiples-cestas 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03767075/a-modular-multi-basket-trial-to-improve-personalized-medicine-in-cancer-patients-basket-of-baskets 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT02715284/estudio-de-tsr-042-un-anticuerpo-monoclonal-anti-receptor-de-muerte-celular-programada-1-pd-1-en-participantes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02715284/study-of-tsr-042-an-anti-programmed-cell-death-1-receptor-pd-1-monoclonal-antibody-in-participants-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03810339/toripalimab-js001-como-terapia-unica-en-participantes-con-tumores-solidos-avanzados-con-mutaciones-en-los-genes-pole-o-pold-1-y-que-no-presentan-msi-h 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03810339/toripalimab-js001-as-monotherapy-in-participants-with-pole-or-pold-1-mutated-and-non-msi-h-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04616534/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-elimusertib-bay-1895344-un-inhibidor-de-atr-al-tratamiento-de-quimioterapia-gemcitabina-para-el-cancer-avanzado-de-pancreas-y-ovario-y-para-tumores 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04616534/testing-the-addition-of-an-anti-cancer-drug-elimusertib-bay-1895344-atr-inhibitor-to-the-chemotherapy-treatment-gemcitabine-for-advanced-pancreatic-and-ovarian-cancer-and-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07288359/estudio-de-gvv858-como-agente-unico-o-en-combinacion-con-terapia-endocrina-en-pacientes-con-cancer-de-mama-hr-her2-y-otros-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07288359/study-of-gvv858-as-a-single-agent-or-in-combination-with-endocrine-therapy-in-patients-with-hr-her2-breast-cancer-and-other-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06586957/un-estudio-con-nkt3964-en-adultos-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06586957/a-study-with-nkt3964-for-adults-with-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06726148/estudio-de-eci830-como-agente-unico-o-en-combinacion-en-pacientes-con-cancer-de-mama-avanzado-hr-her2-y-otros-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06726148/study-of-eci830-single-agent-or-in-combination-in-patients-with-advanced-hr-her2-breast-cancer-and-other-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07029399/un-estudio-con-nkt5097-en-adultos-con-tumores-solidos-avanzados-o-metastasicos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07029399/a-study-with-nkt5097-for-adults-with-advanced-metastatic-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05867251/estudio-de-avzo-021-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05867251/study-of-avzo-021-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07570966/estudio-de-erw316-como-agente-unico-o-en-combinacion-con-terapia-endocrina-en-pacientes-con-cancer-de-mama-hr-her2-y-otros-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570966/study-of-erw316-as-a-single-agent-or-in-combination-with-endocrine-therapy-in-patients-with-hr-her2-breast-cancer-and-other-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05238922/estudio-de-incb123667-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05238922/study-of-incb123667-in-subjects-with-advanced-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07649655/emb-01-en-combinacion-con-quimioterapia-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07649655/emb-01-in-combination-with-chemotherapy-for-unresectable-or-metastatic-colorectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07649473/ql1706-en-combinacion-con-la-terapia-estandar-para-la-terapia-de-conversion-de-metastasis-hepaticas-sincronicas-procedentes-del-cancer-de-colon-un-estudio-exploratorio-multicentrico-y-de-un-solo-brazo 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07649473/ql1706-combined-with-standard-therapy-for-conversion-therapy-of-synchronous-liver-metastases-from-colon-cancer-a-multicenter-single-arm-exploratory-study 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07651553/reseccion-total-mesorrectal-transanal-frente-a-reseccion-total-mesorrectal-robotica 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07651553/transanal-total-mesorectal-excision-vs-robotic-total-mesorectal-excision 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337552/intervencion-con-alimentos-altamente-fermentados-en-pacientes-con-cancer-colorrectal-localmente-avanzado-el-estudio-feed 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337552/high-fermented-food-intervention-among-locally-advanced-rectal-cancer-patients-the-feed-trial 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503639/ensayo-clinico-umbrella-de-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503639/umbrella-trial-of-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07527520/radioterapia-neoadyuvante-con-hipofraccionamiento-moderado-combinada-con-quimioterapia-e-inmunoterapia-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-pmmr-mss-un-ensayo-de-fase-ii 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-multi-center-randomized-control 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07644286/un-estudio-de-fase-ii-de-pirfenidona-mas-un-inhibidor-de-pd-1-con-o-sin-radioterapia-hipofraccionada-para-el-cancer-colorrectal-refractario-pmmr-mss 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07644286/a-phase-ii-study-of-pirfenidone-plus-pd-1-inhibitor-with-or-without-hypofractionated-radiotherapy-for-refractory-pmmr-mss-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06647680/quimioterapia-neoadyuvante-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado-control-01 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06647680/neoadjuvant-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer-control-01 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04928807/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-y-camrelizumab-en-el-cancer-colorrectal-localmente-avanzado-union 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-and-camrelizumab-in-locally-advanced-rectal-cancer-union 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359989/leucina-mas-quimiorradioterapia-para-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359989/leucine-plus-radiochemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-en-combinacion-con-bevacizumab-mas-un-anticuerpo-anti-pd1-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-microsatelital 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-combined-with-bevacizumab-plus-anti-pd1-antibody-as-neoadjuvant-therapy-for-microsatellite-stable-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-para-el-cancer-colorrectal-avanzado-msi-h-dmmr-que-no-responde-al-bloqueo-de-pd-1-pd-l1 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-for-pd-1-pd-l1-blockade-refractory-msi-h-dmmr-advanced-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/inyeccion-de-adebrelimab-pd-l1-combinada-con-radioterapia-de-corta-duracion-y-quimioterapia-para-la-terapia-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/adebrelimab-injection-pd-l1-combined-with-short-course-radiotherapy-and-chemotherapy-for-neoadjuvant-therapy-of-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580339/combinacion-de-dcsz11-con-radioterapia-y-quimioterapia-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03926338/toripalimab-como-tratamiento-neoadyuvante-con-o-sin-celecoxib-en-cancer-colorrectal-con-dmmr-msi-h 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03926338/neoadjuvant-toripalimab-with-or-without-celecoxib-in-dmmr-msi-h-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomida-o-combinacion-de-un-inhibidor-de-mek-e-hidroxicloroquina-para-pacientes-con-mutaciones-en-ras-que-no-responden-al-tratamiento 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomide-or-combination-of-mek-inhibitor-and-hydroxychloroquine-for-refractory-patients-with-ras-mutations 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06888843/estudio-para-evaluar-el-uso-de-capecitabina-en-monoterapia-y-en-combinacion-con-oxaliplatino-en-pacientes-ancianos-como-quimioterapia-adyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/study-to-evaluate-the-use-of-capecitabine-in-monotherapy-and-in-combination-with-oxaliplatin-in-elderly-patients-as-adjuvant-chemotherapy-for-locally-advanced-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-con-o-sin-intensificacion-para-el-cancer-de-recto 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-with-or-without-intensification-for-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/quimioterapia-de-consolidacion-frente-a-quimioterapia-de-induccion-en-la-terapia-neoadyuvante-total-del-cancer-de-recto-con-alto-riesgo-de-recurrencia 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05054959/consolidation-versus-induction-chemotherapy-in-total-neoadjuvant-therapy-of-rectal-cancer-with-high-risk-for-recurrence 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/quimioterapia-neoadyuvante-con-folfirinox-y-quimiorradioterapia-preoperatoria-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/neoadjuvant-folfirinox-and-preoperative-chemoradiotherapy-for-locally-advanced-rectal-cancer-patients 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04230759/radioterapia-y-quimioterapia-con-o-sin-durvalumab-para-el-carcinoma-anal-localmente-avanzado-un-ensayo-multicentrico-aleatorizado-de-fase-ii-del-grupo-de-estudio-del-cancer-anal-aleman 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radiochemotherapy-durvalumab-for-locally-advanced-anal-carcinoma-a-multicenter-randomized-phase-ii-trial-of-the-german-anal-cancer-study-group 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06099951/tratamiento-neoadyuvante-total-para-cancer-colorrectal-localmente-avanzado-con-pmmr-anticuerpo-anti-pd-1-con-folfoxiri-y-radioterapia-preoperatoria 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06099951/total-neoadjuvant-treatment-for-pmmr-locally-advanced-low-rectal-cancer-anti-pd-1-antibody-with-folfoxiri-and-preoperative-radiation-therapy 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05965531/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-quimioterapia-con-tas-102-mas-radioterapia-neoadyuvante 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/treating-locally-advanced-rectal-cancer-with-tas-102-chemotherapy-plus-neoadjuvant-radiotherapy 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-y-durvalumab-en-el-tratamiento-de-pacientes-con-cancer-de-pancreas-avanzado-y-refractario-cancer-de-pulmon-no-microcitico-y-cancer-colorrectal-con-deficiencia-en-la-reparacion-de-errores 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02983578/danvatirsen-and-durvalumab-in-treating-patients-with-advanced-and-refractory-pancreatic-non-small-cell-lung-cancer-and-mismatch-repair-deficient-colorectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949111/radioterapia-terapia-sistemica-como-terapia-de-conversion-para-cancer-de-colon-pmmr-mss-t4m0-neo-color 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radiotherapy-systemic-therapy-as-conversion-therapy-for-pmmr-mss-t4m0-colon-cancer-neo-color 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06507371/radioterapia-de-curso-corto-que-preserva-los-ganglios-combinada-con-capox-y-tislelizumab-para-el-cancer-colorrectal-mss 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06507371/node-sparing-short-course-radiation-combined-with-capox-and-tislelizumab-for-mss-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07467590/combinacion-de-radioterapia-en-dosis-altas-y-bajas-con-inmunoterapia-y-tki-en-cancer-colorrectal-avanzado-un-estudio-de-fase-ii 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combination-of-high-and-low-dose-radiotherapy-with-immune-therapy-and-tki-in-advanced-colorectal-cancer-a-phase-ii-study 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/radioterapia-de-corta-duracion-scrt-seguida-de-6-ciclos-de-cadonilimab-mas-mfolfox6-como-terapia-neoadyuvante-para-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-un-ensayo-multicentrico-de 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/short-course-radiation-scrt-followed-by-6-cycles-of-cadonilimab-plus-mfolfox6-as-neoadjuvant-therapy-for-patients-with-locally-advanced-rectal-cancer-larc-a-multicenter-two-arm-parallel-open-label 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04495088/quimioterapia-folfox-preoperatoria-frente-a-quimioterapia-postoperatoria-adaptada-al-riesgo-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/preoperative-folfox-versus-postoperative-risk-adapted-chemotherapy-in-patients-with-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06929481/deteccion-mediante-un-analisis-de-sangre-para-identificar-el-adn-con-el-fin-de-abordar-las-desigualdades-en-el-cancer-colorrectal 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06929481/screening-with-a-dna-blood-test-to-address-colorectal-cancer-inequities 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05636085/rendimiento-clinico-del-test-de-deteccion-de-cancer-colorrectal-de-mainz-biomed-para-el-cancer-colorrectal-y-el-adenoma-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05636085/clinical-performance-of-the-mainz-biomed-colorectal-cancer-screening-test-for-colorectal-cancer-and-advanced-adenoma 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/un-estudio-de-cohorte-prospectivo-con-diseno-adaptativo-sobre-la-estrategia-de-observacion-y-espera-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/an-adaptive-design-prospective-cohort-study-of-watch-and-wait-strategy-in-patients-with-locally-advanced-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406594/cambios-en-el-microbioma-intestinal-durante-la-terapia-con-abemaciclib-en-el-cancer-de-mama 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406594/gut-microbiome-changes-during-abemaciclib-therapy-in-breast-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/radioterapia-de-corta-duracion-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/short-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06293625/personalizacion-y-optimizacion-de-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-pero-resecable-en-pacientes-de-edad-avanzada-de-70-anos-o-mas 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06293625/personalising-and-refining-neo-adjuvant-chemotherapy-in-locally-advanced-but-resecable-colon-cancer-in-the-elderly-of-70-years-old-or-more 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combinado-con-capox-y-un-inhibidor-de-pd-1-para-el-cancer-colorrectal-de-alto-riesgo 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combined-with-capox-and-pd-1-for-high-risk-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06368141/quimioterapia-neoadyuvante-combinada-con-terapia-secuencial-con-inhibidores-de-puntos-de-control-inmunitario-ici-en-el-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06368141/neoadjuvant-chemotherapy-plus-sequential-immune-checkpoint-inhibitor-ici-therapy-in-locally-advanced-colon-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03776591/colecolectomia-derecha-abierta-versus-colecolectomia-minimamente-invasiva-laparoscopica-para-el-cancer-de-colon-derecho 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03776591/open-d3-right-hemicolectomy-compared-to-laparoscopic-cme-for-right-sided-colon-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07284992/scrt-frente-a-lcrt-seguido-de-un-inhibidor-de-pd-l1-mas-capeox-como-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284992/scrt-vs-lcrt-followed-by-pd-l1-inhibitor-plus-capeox-as-tnt-in-patients-with-larc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-terapias-combinadas-en-el-cancer-colorrectal-metastasico 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-combination-therapies-in-metastatic-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-mas-folfoxiri-frente-a-cetuximab-mas-folfox-en-el-tratamiento-del-cancer-colorrectal-metastasico-crclm 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-plus-folfoxiri-vs-cetuximab-plus-folfox-for-crclm 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05236972/pace-anticuerpo-anti-pd-1-para-el-cancer-colorrectal-en-estadio-iii-con-dmmr-msi-h 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05236972/pace-pd-1-antibody-for-dmmr-msi-h-stage-iii-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07309289/nalirifox-mas-terapia-dirigida-frente-a-folfox-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07309289/nalirifox-plus-targeted-therapy-versus-folfox-plus-targeted-therapy-as-first-line-treatment-for-metastatic-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06301386/everolimus-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06301386/everolimus-combined-with-pd-1-in-advanced-colorectal-cancer-patients 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07505472/comparacion-de-la-eficacia-y-la-seguridad-de-un-ciclo-corto-de-radioterapia-seguido-de-quimioterapia-con-capeox-mas-toripalimab-con-o-sin-surufatinib-concomitante-en-la-terapia-neoadyuvante-para-el 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07505472/efficacy-and-safety-comparison-of-short-course-radiotherapy-followed-by-capeox-chemotherapy-plus-toripalimab-with-or-without-concurrent-surufatinib-in-neoadjuvant-therapy-for-mid-to-low-localized 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509424/radioterapia-neoadyuvante-de-corta-duracion-seguida-de-una-combinacion-de-disitamab-vedotina-sintilimab-y-capecitabina-en-el-cancer-colorrectal-localmente-avanzado-con-expresion-de-her2 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/neoadjuvant-short-course-radiotherapy-followed-by-a-combination-of-disitamab-vedotin-sintilimab-and-capecitabine-in-locally-advanced-her2-expressing-rectal-cance 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06258525/same-en-la-prevencion-de-la-lesion-hepatica-asociada-a-oxaliplatino 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06258525/same-in-prevention-of-oxaliplatin-associated-liver-injury 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-mas-radioterapia-para-la-preservacion-de-organos-en-el-cancer-de-recto 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-plus-radiotherapy-for-organ-preservation-in-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06167967/la-metilacion-del-adn-tumoral-circulante-como-guia-para-la-quimioterapia-adyuvante-postoperatoria-en-el-cancer-colorrectal-en-estadio-iii 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06167967/circulating-tumor-dna-methylation-guiding-postoperative-adjuvant-chemotherapy-in-stage-iii-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07623902/evaluacion-de-la-eficacia-de-gixam-para-predecir-la-presencia-de-neoplasia-colorrectal-avanzada-y-no-avanzada-en-una-poblacion-con-resultados-negativos-en-la-prueba-de-sangre-oculta-en-heces-fit 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07623902/evaluation-of-gixam-s-efficacy-predicting-the-presence-of-advanced-and-non-advanced-colorectal-neoplasia-in-a-fit-negative-population 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07036185/un-ensayo-clinico-de-kj015-en-pacientes-con-tumores-solidos-que-expresan-her2 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07036185/a-clinical-trail-of-kj015-in-patients-with-her2-expressing-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06589440/estudio-de-fase-ii-de-sr-8541a-en-combinacion-con-botensilimab-y-balstilimab-en-sujetos-con-cancer-colorrectal-metastasico-resistente-al-tratamiento-y-con-estabilidad-de-microsatelites-mss-crc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589440/phase-2-study-of-sr-8541a-in-combination-with-botensilimab-and-balstilimab-in-subjects-with-refractory-metastatic-microsatellite-stable-colorectal-cancer-mss-crc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204094/radioterapia-que-preserva-los-ganglios-linfaticos-combinada-con-quimioterapia-neoadyuvante-total-con-capox-y-sintilimab-para-el-cancer-colorrectal-medio-y-bajo-con-mss 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204094/node-sparing-radiotherapy-combined-with-total-neoadjuvant-capox-and-sintilimab-for-mss-middle-and-low-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321106/un-estudio-para-investigar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-de-cbi-1214-un-activador-de-celulas-t-en-participantes-con-cancer-colorrectal-avanzado-o 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321106/a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mss-msi-l-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06882915/eficacia-y-seguridad-de-trifluridina-tipiracil-tas-102-en-combinacion-con-bevacizumab-y-putalimab-en-el-tratamiento-de-pacientes-con-cmmr-despues-de-una-cirugia-citoreductora-un-estudio-clinico-de-un 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/efficacy-and-safety-of-trifluridine-tipiracil-tas-102-combined-with-bevacizumab-and-serplulimab-in-patients-with-metastatic-colorectal-cancer-undergoing-cytoreductive-surgery-a-single-arm-single 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515729/concienciacion-sobre-la-deteccion-del-cancer-colorrectal-en-las-comunidades-de-nativos-americanos 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515729/raising-awareness-of-colorectal-screening-in-american-indian-communities 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03179540/manejo-no-quirurgico-del-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/non-operative-management-for-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06699836/ensayo-de-fase-ii-clover-que-evalua-el-uso-de-leronlimab-un-farmaco-dirigido-al-ccr5-en-combinacion-con-quimioterapia-oral-y-un-regimen-enriquecido-con-un-inhibidor-del-vegf 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06699836/the-phase-2-ccr5-targeting-leronlimab-with-oral-chemotherapy-and-vegf-inhibitor-enriched-regimen-trial-clover 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-in-patients-with-metastatic-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07620535/asesoramiento-y-seguimiento-de-los-pacientes-que-participan-en-el-estudio-shield 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07620535/decision-counseling-and-follow-up-for-shield-patients 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07636382/ablacion-del-plexo-celiaco-para-el-dolor-mediante-radioterapia-estereotactica-sin-necesidad-de-simulacion-en-pacientes-con-dolor-celiaco-relacionado-con-el-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636382/simulation-free-celiac-plexus-pain-ablation-using-stereotactic-body-radiotherapy-in-patients-with-cancer-related-celiac-pain 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03795311/evaluacion-de-la-eficacia-y-la-seguridad-del-tratamiento-con-folfirinox-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-folfirinox-3 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03795311/evaluation-of-the-efficacy-and-the-safety-of-folfirinox3-bevacizumab-treatment-in-patients-with-colorectal-cancer-folfirinox-3 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06783244/presion-intraabdominal-baja-frente-a-presion-intraabdominal-estandar-en-la-cirugia-robotica-del-cancer-colorrectal 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783244/low-versus-standard-intraabdominal-pressure-in-robot-assisted-colorectal-cancer-surgery 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/un-estudio-basket-de-terapias-celulares-autologas-de-tcr-t-personalizadas-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-irresecables 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/a-basket-study-of-customized-autologous-tcr-t-cell-therapies-in-patients-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radioterapia-combinada-con-ql1706-tas-102-y-bevacizumab-en-mcrc 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radiotherapy-combined-ql1706-tas-102-and-bevacizumab-in-mcrc 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05424692/deteccion-de-la-sensibilidad-a-farmacos-en-microtumores-ptc-para-guiar-la-estrategia-de-tratamiento-adyuvante-postoperatorio-del-cancer-colorrectal 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05424692/drug-sensitivity-detection-of-micro-tumor-ptc-to-guide-postoperative-adjuvant-treatment-strategy-of-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04833387/anticuerpo-anti-pd-1-tras-quimiorradioterapia-neoadyuvante-en-cancer-colorrectal-localmente-avanzado-pmmr-mss 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04833387/pd-1-antibody-following-preoperative-chemoradiotherapy-for-locally-advanced-pmmr-mss-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614647/respuesta-atencion-de-seguimiento-para-supervivientes-de-cancer-colorrectal-ahora-es-digital-y-se-basa-en-las-necesidades 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614647/response-colorectal-cancer-survivors-follow-up-care-now-digital-and-need-based 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/diferentes-dosis-de-radioterapia-estereotactica-scrt-mas-capox-bloqueo-de-pd-1-e-il-2-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/different-dose-scrt-plus-capox-pd-1-blockade-and-il-2-in-larc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05723562/un-estudio-de-dostarlimab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-dmmr-msi-h-no-tratados-previamente 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05723562/a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04754672/entrenamiento-de-aptitud-aerobica-o-de-masa-muscular-para-mejorar-el-resultado-en-el-cancer-colorrectal 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/aerobic-fitness-or-muscle-mass-training-to-improve-colorectal-cancer-outcome 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843655/marcadores-radiologicos-en-el-cancer-de-recto-localmente-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/radiological-markers-in-locally-advanced-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06613113/fruquintinib-en-combinacion-con-adebrelimab-y-radioterapia-en-dosis-altas-y-bajas-en-el-tratamiento-del-cancer-colorrectal-metastasico-con-mss-que-ha-progresado-tras-tratamientos-previos-segunda 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613113/fruquintinib-combined-with-adebrelimab-and-high-and-low-dose-radiotherapy-in-the-treatment-of-second-line-and-above-failure-mss-metastatic-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05234177/estudio-de-seguimiento-del-cancer-colorrectal-de-tempus-un-estudio-de-elaboracion-de-perfiles-de-biomarcadores-de-ctdna-en-pacientes-con-cancer-colorrectal-mediante-ensayos-de-ngs 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05234177/tempus-crc-surveillance-study-a-ctdna-biomarker-profiling-study-of-patients-with-crc-using-ngs-assays 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04796818/una-exploracion-de-investigacion-imagen-por-difusion-ponderada-con-el-modelo-de-movimiento-incoherente-intravoxel-para-la-evaluacion-de-la-respuesta-al-tratamiento-de-las-metastasis-hepaticas-del 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04796818/an-investigational-scan-intravoxel-incoherent-motion-diffusion-weighted-imaging-for-the-evaluation-of-colorectal-cancer-liver-metastases-treatment-response 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03981497/ablacion-por-microondas-para-el-tratamiento-de-tumores-renales-pequenos-y-neoplasias-hepaticas-primarias-y-secundarias 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03981497/microwave-ablation-for-treatment-of-small-renal-tumors-and-primary-and-secondary-liver-neoplasms 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/un-estudio-de-fase-ii-realizado-en-un-unico-centro-sobre-la-eficacia-y-la-seguridad-de-la-combinacion-de-radioterapia-estereotactica-scrt-con-quimioterapia-capox-serplulimab-y-bevacizumab-en 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/a-single-center-phase-ii-study-on-efficacy-safety-of-scrt-capox-serplulimab-bevacizumab-for-mss-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07020468/terapia-neoadyuvante-nalirifox-para-el-cancer-colorrectal-localmente-avanzado-y-el-cancer-del-recto-superior 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07020468/neoadjuvant-therapy-nalirifox-for-locally-advanced-colon-and-upper-rectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/estudio-clinico-de-fase-ii-abierto-de-un-unico-centro-para-evaluar-la-eficacia-y-la-seguridad-de-la-inmunoterapia-a-dosis-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-y-cancer-gastrico 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/low-dose-immunotherapy-in-metastatic-and-locally-advanced-colorectal-and-gastric-msi-dmmr-cancers 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06645808/imagen-pet-de-dos-vartumabs-en-pacientes-con-tumores-solidos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645808/pet-imaging-of-two-vartumabs-in-patients-with-solid-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/mesalazina-como-tratamiento-profilactico-para-prevenir-la-colitis-tras-el-tratamiento-con-ipilimumab-nivolumab-ipi-nivo 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/prophylactic-mesalamine-to-prevent-colitis-following-treatment-with-ipilimumab-nivolumab-ipi-nivo 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/un-ensayo-clinico-que-compara-la-anastomosis-de-turnbull-cutait-escalonada-con-la-anastomosis-directa-mas-ileostomia-profilactica-en-el-tratamiento-del-cancer-rectal-bajo-despues-de-la-reseccion-del 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/a-clinical-trial-comparing-staged-turnbull-cutait-pull-through-anastomosis-with-direct-anastomosis-plus-prophylactic-ileostomy-in-the-treatment-of-low-rectal-cancer-after-internal-sphincter-resection 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/evaluacion-de-ivonescimab-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-sin-metastasis-hepaticas 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/testing-ivonescimab-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancers-without-liver-metastases 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553572/aplicacion-digital-para-la-monitorizacion-remota-y-el-manejo-de-los-sintomas 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553572/remote-monitoring-and-symptom-management-digital-application 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03280511/quimioterapia-intraperitoneal-en-aerosol-a-presion-adyuvante-pipac-en-pacientes-con-cancer-de-colon-de-alto-riesgo-sometidos-a-reseccion-quirurgica 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03280511/adjuvant-pressurized-intraperitoneal-aerosol-chemotherapy-pipac-in-resected-high-risk-colon-cancer-patients 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-segunda-linea-en-pacientes-con-mcrc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-plus-bevacizumab-as-a-second-line-therapy-in-mcrc-patients 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/patron-de-tratamiento-y-resultados-en-el-carcinoma-rectal-localmente-avanzado 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/pattern-of-treatment-and-outcomes-of-locally-advanced-rectal-carcinoma 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06210971/quimiorradiacion-neoadyuvante-con-nal-iri-y-capecitabina-guiada-por-el-estado-de-ugt1a1-en-pacientes-con-cancer-de-recto 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/neoadjuvant-chemoradiation-with-nal-iri-and-capecitabine-guided-by-ugt1a1-status-in-patients-with-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04124406/voyage-impacto-en-la-practica-clinica-de-la-prueba-de-adn-fecal-multianalitica-en-la-deteccion-del-ccrc-y-la-mortalidad 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04124406/voyage-real-world-impact-of-the-multi-target-stool-dna-test-on-crc-screening-and-mortality 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07372300/electrohipertermia-modulada-en-combinacion-con-terapia-multimodal-para-el-cancer-de-recto-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/modulated-electro-hyperthermia-in-combination-with-multimodal-therapy-for-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05750329/trasplante-hepatico-con-reseccion-hepatica-en-dos-etapas-en-cancer-de-higado-irresecable-metastasis-o-enfermedad-hepatica-en-etapa-terminal-ltlr-lc 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05750329/liver-transplantation-with-two-stage-liver-resection-in-unresectable-liver-cancer-metastases-or-emd-stage-liver-disease-ltlr-lc 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07132008/quimioterapia-neoadyuvante-con-capox-mas-tislelizumab-frente-a-capox-en-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-mss 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07132008/neoadjuvant-capox-plus-tislelizumab-vs-capox-in-mss-high-risk-locally-advanced-colon-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06234007/radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-adebrelimab-y-capox-en-el-tratamiento-neoadyuvante-completo-del-cancer-colorrectal-localmente-avanzado-un-estudio-multicentrico-de-un-solo 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/short-course-radiotherapy-followed-by-fruquintinib-plus-adebrelimab-and-capox-in-the-full-course-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-a-multicenter-single-arm-open-label-study 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT02572141/quimioterapia-perioperatoria-con-folfox-o-capox-frente-a-quimioterapia-postoperatoria-para-el-cancer-colorrectal-localmente-avanzado-optical 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/folfox-or-capox-perioperative-chemotherapy-versus-postoperative-chemotherapy-for-locally-advanced-colon-cancer-optical 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04845490/estudio-comparativo-de-mitomicina-y-lobaplatino-en-pacientes-con-cancer-colorrectal-avanzado-sometidos-a-cirugia-radical-combinada-con-quimioterapia-intraperitoneal-hiperermica 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/comparative-study-of-mitomycin-and-lobaplatin-in-advanced-colorectal-cancer-patients-with-radical-surgery-combined-with-hyperthermic-intraperitoneal-chemotherapy 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06456229/tiempo-hasta-la-recuperacion-de-la-funcion-intestinal-tras-la-administracion-de-probioticos-en-el-periodo-perioperatorio-en-la-cirugia-de-cancer-colorrectal 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456229/time-to-return-of-bowel-function-following-perioperative-probiotics-in-colorectal-cancer-surgery 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06858969/chidamida-en-combinacion-con-un-inhibidor-de-pd-1-bevacizumab-y-xelox-para-el-cancer-colorrectal-metastasico 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06858969/chidamide-in-combination-with-pd-1-inhibitor-bevacizumab-and-xelox-for-metastatic-colorectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06179602/estudio-de-cohorte-prospectivo-sobre-la-ablacion-termica-de-tumores-hepaticos-malignos 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/prospective-cohort-study-on-thermal-ablation-of-malignant-liver-tumors 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/regimen-terapeutico-sandwich-modificado-para-el-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/modified-sandwich-therapeutic-regimen-for-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07384377/jskn003-frente-al-tratamiento-elegido-por-el-medico-en-pacientes-con-cancer-colorrectal-avanzado-her2-positivo-que-no-habian-respondido-a-oxaliplatino-5-fu-e-irinotecan 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07384377/jskn003-versus-physician-choiced-treatment-in-patients-with-her2-positive-and-advanced-colorectal-cancer-who-had-failed-to-respond-to-oxaliplatin-5-fu-and-irinotecan 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/quimioterapia-neoadyuvante-con-mfolfox6-combinada-con-terapia-anti-pd-1-en-cancer-colorrectal-localmente-avanzado-mss-pmmr-estudio-firm02 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/neoadjuvant-mfolfox6-chemotherapy-combined-with-anti-pd-1-therapy-in-mss-pmmr-locally-advanced-rectal-cancer-firm02-study 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07385521/el-uso-de-la-inteligencia-artificial-para-la-prediccion-de-la-recurrencia-tras-la-reseccion-de-metastasis-hepaticas-de-cancer-colorrectal 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07385521/the-use-of-artificial-intelligence-for-the-prediction-of-recurrence-after-resection-of-colorectal-liver-metastases 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-en-combinacion-con-quimioterapia-metronomica-multimodal-para-cancer-colorrectal-metastasico-resistente-a-la-quimioterapia 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-in-combination-with-multimodal-metronomic-chemotherapy-for-chemo-resistant-metastatic-colorectal-cancers 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT04464668/concienciacion-investigacion-educacion-y-deteccion-del-cancer-colorrectal-ampliacion-acceso-y-mejora-de-la-capacidad-en-zonas-rurales 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT04464668/colorectal-cancer-awareness-research-and-education-and-screening-rural-expansion-access-and-capacity-for-health 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07392567/validacion-prospectiva-de-un-modelo-de-inteligencia-artificial-para-predecir-la-metastasis-hepatica-en-el-cancer-colorrectal 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07392567/prospective-validation-of-an-ai-model-for-predicting-liver-metastasis-in-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06528353/deteccion-mediante-biomarcadores-sanguineos-en-el-cribado-de-cpc-impulsado-por-el-vph 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06528353/blood-biomarkers-based-screening-for-hpv-driven-opc 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06753136/electroquimioterapia-ect-en-pacientes-con-tumores-viscerales-primarios-y-o-localizaciones-viscerales-secundarias-de-cualquier-histotipo 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electrochemotherapy-ect-in-patients-with-primary-visceral-tumors-and-or-secondary-visceral-localizations-of-any-histotype 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06963502/un-estudio-de-fase-ib-de-hs-10370-en-combinacion-con-otras-terapias-antineoplasicas-en-pacientes-con-tumores-solidos-avanzados 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT06963502/a-phase-ib-study-of-hs-10370-in-addition-to-other-anti-cancer-therapies-in-patients-with-advanced-solid-tumors 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT05720559/estrategia-de-bloqueo-temprano-para-la-metastasis-hepatica-sincronica-del-cancer-colorrectal-basada-en-la-deteccion-prehepatica-de-ctc 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT05720559/early-blocking-strategy-for-metachronous-liver-metastasis-of-colorectal-cancer-based-on-pre-hepatic-ctc-detection 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07581912/tratamiento-neoadyuvante-con-fulzerasib-mas-cetuximab-n01-en-cancer-colorrectal-localmente-avanzado-con-mutacion-kras-g12c-con-o-sin-metastasis-resecables 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07581912/neoadjuvant-treatment-of-fulzerasib-plus-cetuximab-n01-in-kras-g12c-mutated-locally-advanced-colorectal-cancer-with-or-without-resectable-metastases 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06689293/estudio-sobre-el-uso-de-pruebas-inmunoquimicas-fecales-fit-para-la-vigilancia-tras-el-cancer-colorrectal-crc 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06689293/faecal-immunochemical-tests-fit-for-surveillance-after-colorectal-cancer-crc-study 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-dostarlimab-neoadyuvante-con-radioterapia-de-corta-duracion-en-una-estrategia-de-observacion-y-espera-para-pacientes-con-cancer-colorrectal-localmente-avanzado-inestable-en 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-neoadjuvant-dostarlimab-with-short-course-radiotherapy-in-a-watch-and-wait-strategy-for-microsatellite-unstable-or-mismatch-repair-deficient-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/tratamiento-neoadyuvante-total-con-o-sin-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/total-neoadjuvant-treatment-with-or-without-tislelizumab-for-locally-advanced-rectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07403877/inmunoterapia-neoadyuvante-radioterapia-en-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403877/neoadjuvant-immunotherapy-radiotherapy-in-msi-h-dmmr-locally-advanced-colorectal-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07044921/estudio-clinico-de-un-tratamiento-combinado-basado-en-irinotecan-liposomal-ii-para-el-cancer-colorrectal-resistente-al-irinotecan 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/clinical-study-of-irinotecan-liposome-ii-based-combination-treatment-for-irinotecan-resistant-colorectal-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparacion-de-la-radioterapia-abdominal-guiada-por-pet-con-68ga-fapi-combinada-con-la-terapia-estandar-de-segunda-linea-y-cadonilimab-frente-a-la-terapia-estandar-de-segunda-linea-en-el-cancer 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparing-18f-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis 2026-06-18 weekly 0.7 https://crcwarriors.org/ensayo/NCT07404228/estudio-multidimensional-disenado-para-desarrollar-un-marco-metodologico-basado-en-datos-de-resonancia-magnetica-rm-con-el-fin-de-predecir-la-respuesta-patologica-completa-pcr-en-pacientes-con-cancer 2026-06-18 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/multidimensional-study-designed-to-develop-a-methodological-framework-based-on-mri-data-to-predict-pathological-complete-response-pcr-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/oxaliplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibrutinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibrutinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngr-htnf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngr-htnf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/venetoclax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/venetoclax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gm-ct-01 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/gm-ct-01/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/napabucasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/napabucasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tnt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tnt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2391/efecto-de-uno-o-dos-ciclos-de-inmunoterapia-combinada-con-nivolumab-e-ipilimumab-en-pacientes-con-cancer-colorrectal-con-deficiencia-en-la-reparacion-de-errores-reset-r-resultados-preliminares-de-un 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2391/effect-of-one-or-two-cycles-of-dual-immunotherapy-with-nivolumab-and-ipilimumab-in-patients-with-mismatch-repair-deficient-rectal-cancer-reset-r-interim-results-from-a-multicentre-single-arm-phase-2 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2379/dirigirse-a-la-separacion-de-fases-liquido-liquido-de-aven-en-el-cancer-colorrectal-hallazgos-derivados-de-una-sonda-quimica-basada-en-raddeanina-a 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2379/targeting-aven-liquid-liquid-phase-separation-in-colorectal-cancer-insights-from-a-raddeanin-a-based-chemical-probe 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2374/los-subtipos-moleculares-consensuados-proporcionan-informacion-para-la-seleccion-del-agente-en-la-quimioterapia-hipertermia-intraperitoneal-hipec-en-las-metastasis-peritoneales-del-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2374/consensus-molecular-subtypes-inform-hipec-agent-selection-in-colorectal-cancer-peritoneal-metastases 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2373/el-papel-pronostico-de-la-inflamacion-postoperatoria-tras-la-reseccion-minimamente-invasiva-del-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2373/the-prognostic-role-of-postoperative-inflammation-after-minimally-invasive-resection-for-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2341/vasculatura-funcional-en-organoides-tumorales-facilitando-la-medicina-de-precision-en-oncologia 2026-06-12 monthly 0.5 https://crcwarriors.org/articulo/2341/functional-vasculature-in-tumor-organoids-enabling-precision-medicine-in-oncology 2026-06-12 monthly 0.5 https://crcwarriors.org/articulo/2327/la-carga-mutacional-tumoral-evaluada-en-tejidos-y-sangre-predice-la-respuesta-al-tratamiento-con-inhibidores-de-pd-1-en-el-carcinoma-de-celulas-escamosas-de-cabeza-y-cuello-una-revision-sistematica-y 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2327/tissue-and-blood-based-tumor-mutational-burden-predicts-treatment-response-to-pd-1-blockade-in-head-and-neck-squamous-cell-carcinoma-a-systematic-review-and-meta-analysis 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2294/superacion-de-la-resistencia-inmune-condicional-en-el-cancer-colorrectal-mss-y-pmmr-un-modelo-de-secuenciacion-escalonada-para-la-inmunoterapia 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2294/overcoming-conditional-immune-resistance-in-mss-and-pmmr-colorectal-cancer-a-sequential-gating-framework-for-immunotherapy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2293/el-receptor-de-vitamina-d-en-los-tumores-una-revision-de-los-mecanismos-biologicos-los-posibles-usos-terapeuticos-y-los-valores-pronosticos 2026-06-15 monthly 0.5 https://crcwarriors.org/articulo/2293/vitamin-d-receptor-in-tumors-a-review-of-biological-mechanisms-therapeutic-potentials-and-prognostic-values 2026-06-15 monthly 0.5 https://crcwarriors.org/articulo/2280/la-ferroptosis-en-el-cancer-colorrectal-mecanismos-moleculares-y-la-interaccion-reguladora-con-posibles-aplicaciones-terapeuticas-revision 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2280/ferroptosis-in-colorectal-cancer-molecular-mechanisms-and-regulatory-crosstalk-with-therapeutic-prospects-review 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2261/quimiorradioterapia-adyuvante-frente-a-reseccion-total-del-meso-recto-complementaria-tras-reseccion-local-para-el-cancer-de-recto-en-estadio-temprano-tesar-un-ensayo-multicentrico-aleatorizado 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2261/adjuvant-chemoradiotherapy-versus-completion-total-mesorectal-excision-after-local-excision-for-early-rectal-cancer-tesar-a-multicentre-randomised-controlled-phase-3-non-inferiority-trial 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2257/la-neferina-al-potenciar-la-formula-shenling-baizhu-tang-refuerza-la-terapia-anti-pd-1-en-las-metastasis-hepaticas-del-cancer-colorrectal-a-traves-de-la-reprogramacion-lipidica-mediada-por-cyp2e1-ppar 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2257/neferine-enhanced-shenling-baizhu-tang-potentiates-anti-pd-1-therapy-in-colorectal-cancer-liver-metastasis-via-cyp2e1-ppar-mediated-lipid-reprogramming 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2232/la-plataforma-de-oncologia-de-precision-funcional-de-organoides-de-cancer-colorrectal-con-mutacion-braf-v600e-predice-la-respuesta-al-tratamiento-y-revela-la-inmunogenicidad-mediada-por-rnf43 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2232/functional-precision-oncology-platform-of-braf-v600e-mutated-colorectal-cancer-organoids-predicts-therapy-response-and-reveals-rnf43-mediated-immunogenicity 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluacion-del-ct-adn-y-el-estado-mutacional-en-la-biopsia-liquida-de-pacientes-con-cancer-colorrectal-metastasico 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluation-of-ct-dna-and-mutational-status-in-liquid-biopsy-of-patients-with-metastatic-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2038/sotorasib-mas-panitumumab-y-5-fluorouracilo-en-el-tratamiento-de-primera-linea-de-pacientes-con-cancer-colorrectal-irresecable-con-mutacion-kras-g12c-que-no-son-aptos-para-quimioterapia-combinada 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2038/sotorasib-plus-panitumumab-and-5-fluorouracil-in-first-line-treatment-of-patients-with-unresectable-kras-g12c-mutated-colorectal-cancer-unfit-for-a-doublet-triplet-chemotherapy-engic-01-prodige-107 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1996/los-conjugados-peptido-farmaco-que-contienen-la-carga-antimitotica-ahx-da1-logran-una-potente-actividad-antitumoral-en-modelos-in-vivo-de-canceres-con-amplificacion-de-her2-positivos-para-egfr-y-con 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1996/peptide-drug-conjugates-bearing-an-antimitotic-ahx-da1-payload-achieve-potent-antitumor-activity-in-her2-amplified-and-egfr-positive-kras-mutant-cancers-in-vivo 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1963/analisis-basado-en-secuenciacion-de-siguiente-generacion-del-espectro-de-mutaciones-geneticas-en-cancer-colorrectal-un-estudio-de-gran-escala-de-un-unico-centro-del-sureste-de-china-con-comparacion 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1963/next-generation-sequencing-based-analysis-of-the-genetic-mutation-spectrum-in-colorectal-cancer-a-large-single-center-study-from-southeast-china-with-cross-population-comparison 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1959/resumen-visual-de-aso-la-combinacion-de-mutaciones-en-ras-y-smad4-junto-con-la-inestabilidad-de-microsatelites-predice-los-resultados-en-metastasis-pulmonares-de-cancer-colorrectal-tratadas-con 2026-06-11 monthly 0.5 https://crcwarriors.org/articulo/1959/aso-visual-abstract-combined-ras-and-smad4-mutations-and-microsatellite-instability-predict-outcomes-in-colorectal-lung-metastases-treated-with-image-guided-thermal-ablation 2026-06-11 monthly 0.5 https://crcwarriors.org/articulo/1922/runx1-activa-directamente-a-wnt2-para-orquestar-la-reprogramacion-de-los-macrofagos-asociados-al-tumor-en-el-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1922/runx1-directly-activates-wnt2-to-orchestrate-tumor-associated-macrophage-reprogramming-in-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1912/mutaciones-combinadas-de-ras-y-smad4-e-inestabilidad-de-microsatelites-predicen-los-resultados-en-metastasis-pulmonares-colorrectales-tratadas-con-ablacion-termica-guiada-por-imagen 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1912/combined-ras-and-smad4-mutations-and-microsatellite-instability-predict-outcomes-in-colorectal-lung-metastases-treated-with-image-guided-thermal-ablation 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1698/displasia-en-lesiones-serradas-sesiles-frecuencia-variabilidad-interobservador-y-valor-anadido-de-la-inmunohistoquimica 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1698/dysplasia-in-sessile-serrated-lesions-frequency-interobserver-variability-and-added-value-of-immunohistochemistry 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1623/las-probioticos-ingenierizados-despojados-de-metionina-promueven-la-inmunoterapia-con-anticuerpos-anti-pd-l1-al-activar-el-camino-sting 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1623/methionine-depleting-engineered-probiotics-promote-pd-l1-antibody-immunotherapy-by-activating-the-sting-pathway 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1607/aplicar-reguladores-nanomimeticos-para-fototerapia-in-situ-y-regulacion-de-lactato-con-el-fin-de-amplificar-la-terapia-inmunitaria-cuproptosis 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/1607/harnessing-biomimetic-nano-regulators-for-in-situ-photothermia-and-lactate-regulation-to-amplify-cuproptosis-immunotherapy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2407/un-nuevo-conjugado-anticuerpo-farmaco-disenado-para-dirigirse-a-b7-h3-demuestra-una-mayor-eficacia-terapeutica-en-una-amplia-gama-de-canceres 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2407/a-newly-designed-antibody-drug-conjugate-targeting-b7-h3-demonstrates-enhanced-therapeutic-efficacy-across-a-spectrum-of-cancers 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2406/respuesta-completa-sostenida-al-tratamiento-con-la-plataforma-tmep-ci-m-en-un-cancer-de-pulmon-de-celulas-pequenas-refractario-con-metastasis-en-el-tronco-encefalico-informe-de-un-caso-con-mas-de-20 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2406/sustained-complete-response-to-tmep-ci-m-platform-in-refractory-small-cell-lung-cancer-with-brainstem-metastasis-a-case-report-with-over-20-months-of-disease-free-survival 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2405/eficacia-y-seguridad-comparativas-de-los-tratamientos-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-ras-tipo-salvaje-una-revision-sistematica-y-un-metaanalisis-de-red 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2405/comparative-efficacy-and-safety-of-first-line-treatments-for-ras-wild-type-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2404/renovacion-del-aire-en-el-dormitorio-como-terapia-adyuvante-antiinflamatoria-en-supervivientes-de-cancer-protocolo-para-la-serie-de-ensayos-aleatorizados-controlados-con-placebo-breaths-n-of-1 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2404/in-bedroom-renewed-air-as-anti-inflammatory-adjuvant-therapy-in-cancer-survivors-protocol-for-the-randomised-placebo-controlled-breaths-n-of-1-trial-series 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2403/resistencia-a-la-inmunoterapia-en-el-cancer-colorrectal-estrategias-terapeuticas-y-enfoques-guiados-por-biomarcadores 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2403/immunotherapy-resistance-in-colorectal-cancer-therapeutic-strategies-and-biomarker-guided-approaches 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2401/factores-de-riesgo-tipos-de-cancer-y-significado-pronostico-del-segundo-cancer-primario-tras-el-cancer-colorrectal-de-inicio-temprano-intermedio-y-tardio-un-estudio-retrospectivo-en-un-centro 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2401/risk-factors-cancer-types-and-prognostic-significance-of-second-primary-cancer-after-early-intermediate-and-late-onset-colorectal-cancer-a-retrospective-study-in-a-chinese-high-volume-cancer-center 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2400/erlotinib-mas-bevacizumab-en-tumores-solidos-metastasicos-con-amplificacion-de-egfr-resultados-del-estudio-kosmos-i-ii-que-evalua-la-terapia-guiada-por-el-perfilado-molecular-en-canceres-avanzados 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2400/erlotinib-plus-bevacizumab-in-egfr-amplified-metastatic-solid-tumors-results-from-the-kosmos-i-ii-study-of-molecular-profiling-guided-therapy-in-advanced-cancers 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2399/interaccion-entre-las-vias-de-muerte-celular-metabolica-en-el-cancer-colorrectal-implicaciones-para-la-terapia-de-precision 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2399/crosstalk-of-metabolic-cell-death-pathways-in-colorectal-cancer-implications-for-precision-therapy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2398/evaluacion-de-la-mesotelina-como-un-blanco-inmunoterapeutico-para-las-celulas-t-endogenas 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2398/evaluating-mesothelin-as-an-immunotherapeutic-target-for-endogenous-t-cells 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2397/la-edicion-del-arn-a-nivel-de-celula-unica-identifica-a-adar1-en-las-celulas-t-como-un-regulador-clave-del-agotamiento-inmunitario-y-la-resistencia-anti-pd-1-en-el-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2397/single-cell-rna-editing-identifies-t-cell-adar1-as-a-key-regulator-of-immune-exhaustion-and-anti-pd-1-resistance-in-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2395/un-enfoque-probiotico-dirigido-a-la-hipersialilacion-revitaliza-la-inmunidad-de-las-celulas-t-cd8-y-mejora-la-eficacia-de-la-terapia-fotodinamica-en-tumores-solidos 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2395/a-probiotic-approach-targeting-hypersialylation-revives-cd8-t-cell-immunity-and-boosts-photodynamic-therapy-efficacy-in-solid-tumors 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2394/un-modelo-clinico-radiologico-que-integra-la-composicion-corporal-basal-obtenida-mediante-tomografia-computarizada-para-predecir-el-pronostico-en-pacientes-con-cancer-colorrectal-metastasico-tratados 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2394/a-clinico-radiological-model-integrating-baseline-ct-derived-body-composition-to-predict-prognosis-in-immunotherapy-treated-metastatic-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2393/diferencias-raciales-y-etnicas-en-los-resultados-del-cribado-del-cancer-de-prostata-en-los-estados-unidos-un-analisis-secundario-del-ensayo-sobre-el-cancer-de-prostata-pulmon-colon-y-ovario 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2393/racial-and-ethnic-differences-in-prostate-cancer-screening-outcomes-in-the-united-states-a-secondary-analysis-of-the-prostate-lung-colorectal-and-ovarian-cancer-trial 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2392/caracteristicas-moleculares-de-pacientes-chinos-con-cancer-colorrectal-y-inestabilidad-de-microsatelites 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2392/molecular-characteristics-of-chinese-colorectal-cancer-patients-with-microsatellite-instability 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2390/el-analisis-transcriptomico-de-celulas-individuales-revela-la-heterogeneidad-y-la-dinamica-del-agotamiento-de-las-celulas-t-citotoxicas-cd27-en-el-microambiente-tumoral-del-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2390/single-cell-transcriptomic-profiling-reveals-cd27-cytotoxic-t-cell-heterogeneity-and-exhaustion-dynamics-in-colorectal-cancer-tumor-microenvironment 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2389/inmunoterapia-y-toma-de-decisiones-quirurgicas-en-el-cancer-colorrectal-asociado-al-sindrome-de-lynch-implicaciones-para-el-manejo-personalizado-y-la-revision-de-las-guias-clinicas 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2389/immunotherapy-and-surgical-decision-making-in-lynch-syndrome-associated-colorectal-cancer-implications-for-personalized-management-and-guideline-revision 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2385/la-quimioinmunoterapia-permite-implementar-estrategias-adaptativas-en-el-cancer-colorrectal-localmente-avanzado-mss 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2385/chemoimmunotherapy-enables-adaptive-strategies-in-locally-advanced-mss-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2384/bloqueo-dual-de-ctla-4-pd-1-frente-a-anti-pd-1-en-cancer-colorrectal-metastasico-msi-h-beneficio-temprano-en-la-supervivencia-y-predictores-clinicos-exploratorios 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2384/dual-ctla-4-pd-1-blockade-versus-anti-pd-1-in-msi-h-metastatic-colorectal-cancer-early-survival-benefit-and-exploratory-clinical-predictors 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2383/mejora-de-la-respuesta-inmunoterapeutica-en-el-cancer-colorrectal-mediante-un-peptido-tumoral-que-penetra-en-el-tumor-y-se-dirige-a-la-neuropilina-1 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2383/enhancing-immunotherapeutic-response-in-colorectal-cancer-with-a-neuropilin-1-targeting-tumor-penetrating-peptide 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2380/terapia-dirigida-a-braf-en-tumores-no-melanoma-con-mutacion-braf-una-revision-sistematica-de-la-eficacia-que-es-amplia-pero-modulada-segun-el-tipo-histologico 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2380/braf-targeted-therapy-in-non-melanomatous-braf-mutant-tumours-a-systematic-review-of-broad-but-histology-modulated-efficacy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2378/beclin-1-como-biomarcador-de-la-autofagia-en-el-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2378/beclin-1-as-an-autophagy-biomarker-in-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2377/biomarcadores-emergentes-para-la-deteccion-precoz-del-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2377/emerging-biomarkers-for-early-detection-of-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2376/asociacion-entre-el-grupo-sanguineo-abo-y-la-supervivencia-en-el-cancer-de-colon-en-estadio-temprano-un-analisis-retrospectivo-de-cohortes-realizado-en-un-unico-centro 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2376/association-between-abo-blood-group-and-survival-in-early-stage-colon-cancer-a-single-center-retrospective-cohort-analysis 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2375/la-reprogramacion-transcripcional-de-las-celulas-treg-que-varia-segun-el-sitio-en-un-modelo-de-cancer-colorrectal-metastasico-tiene-importancia-pronostica 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2375/site-dependent-treg-cell-transcriptional-reprograming-in-a-metastatic-colorectal-cancer-model-holds-prognostic-significance 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2372/descubrimiento-de-un-nuevo-y-potente-peptido-dirigido-a-kras-g12v-con-actividad-antiproliferativa-contra-celulas-de-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2372/discovery-of-a-novel-and-potent-kras-g12v-targeting-peptide-with-antiproliferative-activity-against-colorectal-cancer-cells 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2371/los-factores-clinicos-estan-mas-fuertemente-asociados-con-el-pronostico-que-las-alteraciones-geneticas-en-el-cancer-colorrectal-de-inicio-temprano-un-estudio-retrospectivo-de-cohortes 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2371/clinical-factors-are-more-strongly-associated-with-prognosis-than-genetic-alterations-in-early-onset-colorectal-cancer-a-retrospective-cohort-study 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2370/un-mecanismo-dual-de-evasion-inmune-moldea-el-panorama-genetico-e-inmunogenico-de-los-tumores-colorrectales-con-deficiencia-en-la-reparacion-de-errores 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2370/dual-mechanism-of-immune-escape-shapes-the-genetic-and-immunogenic-landscape-of-mismatch-repair-deficient-colorectal-tumours 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2365/la-decoccion-sanwu-huangqin-induce-la-ferroptosis-en-las-celulas-de-cancer-colorrectal-al-activar-la-ferritinafagia-mediada-por-ncoa4-fth1 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2365/sanwu-huangqin-decoction-induces-ferroptosis-in-colorectal-cancer-cells-by-triggering-ncoa4-fth1-mediated-ferritinophagy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2364/biomarcadores-predictivos-en-pacientes-con-cancer-colorrectal-metastasico-tratados-con-bevacizumab-un-estudio-del-grupo-de-oncologia-turco-tog 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2364/predictive-biomarkers-in-metastatic-colorectal-cancer-patients-treated-with-bevacizumab-a-turkish-oncology-group-tog-study 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2363/dirigirse-a-la-ferroptosis-para-superar-la-radioresistencia-y-mejorar-la-inmunoterapia-en-el-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2363/targeting-ferroptosis-to-overcome-radioresistance-and-enhance-immunotherapy-in-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2362/los-degradadores-moleculares-que-se-unen-a-hur-suprimen-el-cancer-colorrectal-con-mutacion-en-el-gen-braf 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2362/molecular-glue-degraders-of-hur-suppress-braf-mutant-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2361/analisis-de-los-factores-de-riesgo-y-las-diferencias-sexuales-en-el-cancer-colorrectal-hallazgos-basados-en-la-evidencia-actual 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2361/exploring-risk-factors-and-sex-differences-in-colorectal-cancer-insights-from-current-evidence 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2357/sonda-fluorescente-de-infrarrojo-cercano-nir-ii-dirigida-a-vegfr2-para-la-obtencion-de-imagenes-precisas-y-la-guia-quirurgica-del-cancer-de-ovario 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2357/vegfr2-targeted-nir-ii-fluorescent-probe-for-precise-imaging-and-surgical-navigation-of-ovarian-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2353/nanoagonista-dirigido-a-base-de-zinc-con-respuesta-dual-a-tme-nir-para-la-amplificacion-multimodal-de-la-inmunoterapia-contra-el-cancer-mediada-por-sting 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2353/tme-nir-dual-responsive-zinc-based-targeted-nanoagonist-for-multimodal-amplification-of-sting-mediated-cancer-immunotherapy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-la-integracion-de-aprendizaje-profundo-y-metodos-estadisticos-revela-patrones-espaciales-del-estroma-y-del-sistema-inmunitario-en-el-cancer-colorrectal-agresivo 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2352/timel-deep-learning-statistical-integration-reveals-spatial-stromal-and-immune-signatures-of-aggressive-colon-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2351/la-lidocaina-potencia-los-efectos-antitumorales-del-sorafenib-y-el-gw5074-en-celulas-de-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2351/lidocaine-enhances-antitumor-effects-of-sorafenib-and-gw5074-in-colorectal-cancer-cells 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2349/la-combinacion-del-inhibidor-de-kras-g12c-adagrasib-con-inmunoterapia-anti-pd-1-mejora-la-supervivencia-global-y-previene-la-recurrencia-en-modelos-preclinicos-de-metastasis-cerebrales 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2349/combining-the-kras-g12c-inhibitor-adagrasib-with-anti-pd-1-immunotherapy-improves-overall-survival-and-prevents-recurrence-in-preclinical-models-of-brain-metastasis 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2340/hidrogel-anaerobico-inyectable-que-contiene-clostridium-butyricum-para-la-administracion-local-de-hidrogeno-en-el-tratamiento-del-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2340/injectable-anaerobic-hydrogel-loading-clostridium-butyricum-for-local-hydrogen-therapy-against-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2338/ausencia-de-coexistencia-entre-la-amplificacion-de-her2-y-la-inestabilidad-de-microsatelites-deficiencia-de-reparacion-de-errores-dmmr-msi-en-una-amplia-cohorte-multicentrica-de-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2338/absence-of-co-occurrence-between-her2-amplification-and-dmmr-msi-in-a-large-multicentric-colorectal-cancer-cohort 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2337/impacto-de-la-certificacion-del-oncologo-medico-en-los-resultados-de-supervivencia-en-el-cancer-colorrectal-metastasico-evidencia-del-estudio-observacional-scrum-japan-monstar-screen 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2337/impact-of-medical-oncologist-certification-on-survival-outcomes-in-metastatic-colorectal-cancer-evidence-from-the-scrum-japan-monstar-screen-observational-study 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2335/resumen-ejecutivo-de-los-criterios-de-uso-adecuado-de-la-sociedad-americana-de-radio-para-el-tratamiento-del-cancer-de-recto-con-recurrencia-locorregional 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2335/executive-summary-of-american-radium-society-appropriate-use-criteria-for-the-treatment-of-locoregionally-recurrent-rectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2334/tratamiento-satisfactorio-del-cancer-colorrectal-metastasico-con-mutacion-braf-v600e-y-disfuncion-hepatica-mediante-una-terapia-basada-en-encorafenib 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2334/successful-management-of-braf-v600e-mutated-metastatic-colorectal-cancer-with-liver-dysfunction-using-encorafenib-based-therapy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2333/farmacoterapia-personalizada-del-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2333/personalized-pharmacotherapy-of-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2332/desarrollo-y-evaluacion-in-vivo-de-marcadores-de-pet-marcados-con-18-f-que-se-unen-de-forma-covalente-al-kras-g12c-para-el-diagnostico-no-invasivo-del-cancer-y-el-seguimiento-del-tratamiento 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2332/development-and-in-vivo-evaluation-of-18-f-labeled-pet-tracers-covalently-targeting-kras-g12c-for-noninvasive-cancer-diagnosis-and-therapy-monitoring 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2331/de-la-dosis-a-la-exposicion-una-nueva-perspectiva-sobre-los-fluoropirimidinicos-como-posibles-moduladores-de-los-puntos-de-control-inmunitario-en-los-canceres-gastrointestinales 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2331/from-dose-to-exposure-rethinking-fluoropyrimidines-as-immune-checkpoint-partners-in-gastrointestinal-cancers 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2330/terapia-con-celulas-t-modificadas-con-receptores-quimericos-dirigidos-a-la-guanilato-ciclasa-2c-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2330/guanylyl-cyclase-2c-targeted-chimeric-antigen-receptor-t-cell-therapy-in-patients-with-metastatic-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2322/investigacion-de-la-eficacia-del-propranolol-en-el-tratamiento-del-estres-cronico-combinado-con-cancer-colorrectal-en-ratones-y-su-potencial-antitumoral 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2322/investigating-the-efficacy-of-propranolol-in-treating-chronic-stress-combined-with-colorectal-cancer-in-mice-and-its-antitumor-potential 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2318/sorafenib-anclado-sobre-negro-de-carbon-como-un-electrocatalizador-redox-molecular-estable-para-la-oxidacion-de-tioles-y-la-deteccion-en-el-punto-de-atencion-en-celulas-cancerosas 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2318/anchored-sorafenib-on-carbon-black-as-a-stable-molecular-redox-electrocatalyst-for-thiol-oxidation-and-point-of-care-sensing-in-cancer-cells 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2317/alteraciones-especificas-del-subtipo-en-el-transporte-de-cobre-asociadas-con-las-mutaciones-de-kras-en-lineas-celulares-isogenicas-de-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2317/subtype-specific-alterations-in-copper-trafficking-associated-with-kras-mutations-in-isogenic-colorectal-cancer-cell-lines 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2316/la-delecion-de-egfr-en-celulas-mieloides-reprograma-el-paisaje-inmunosupresor-del-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2316/egfr-deletion-in-myeloid-cells-reprograms-the-immunosuppressive-landscape-of-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2314/papel-emergente-de-los-conjugados-anticuerpo-farmaco-en-las-neoplasias-gastrointestinales 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2314/emerging-role-of-antibody-drug-conjugates-in-gastrointestinal-malignancies 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2313/la-modulacion-dirigida-del-tnf-potencia-la-actividad-de-los-anticuerpos-bispecificos-que-activan-las-celulas-t-en-tumores-solidos-transformando-tumores-frios-en-tumores-calientes 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2313/targeted-tnf-potentiates-the-activity-of-bispecific-t-cell-engagers-in-solid-tumors-by-turning-cold-tumors-hot 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2311/revision-exhaustiva-de-la-inmunoterapia-en-el-cancer-colorrectal-desde-los-mecanismos-hasta-las-intervenciones-de-enfermeria 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2311/comprehensive-review-of-immunotherapy-in-colorectal-cancer-from-mechanisms-to-nursing-interventions 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2310/kras-g12r-en-el-cancer-de-pancreas-por-que-esta-mutacion-resiste-a-las-estrategias-inhibidoras-actuales 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2310/kras-g12r-in-pancreatic-cancer-why-this-mutation-resists-current-inhibitor-strategies 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2306/discriminacion-precisa-de-polimorfismos-de-un-solo-nucleotido-mediante-el-ensamblaje-de-sondas-de-bloqueo-mediadas-por-pna-y-la-amplificacion-por-circulo-rodante-utilizando-pna-modificado-quimicamente 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2306/precision-discrimination-of-single-nucleotide-polymorphisms-via-chemically-engineered-pna-mediated-padlock-probe-assembly-and-rolling-circle-amplification 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2305/avances-recientes-en-las-plataformas-de-biosensores-que-utilizan-la-caracterizacion-de-biomarcadores-exosomicos-para-el-diagnostico-del-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2305/recent-advances-in-biosensing-platforms-utilizing-exosomal-biomarker-profiling-for-cancer-diagnosis 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2303/sintesis-y-evaluacion-preclinica-de-89-zr-dfo-atezolizumab-para-la-imagen-pet-inmunitaria-en-el-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2303/synthesis-and-preclinical-evaluation-of-89-zr-dfo-atezolizumab-for-immuno-pet-imaging-in-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2302/mas-alla-del-5-fluorouracilo-convencional-estrategias-recientes-de-quimica-medicinal-para-mejorar-su-eficacia-antitumoral 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2302/beyond-conventional-5-fluorouracil-recent-medicinal-chemistry-strategies-to-enhance-its-anticancer-efficacy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2301/un-nuevo-inhibidor-no-competitivo-de-p97-vcp-induce-apoptosis-y-autofagia-para-suprimir-el-crecimiento-del-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2301/a-novel-non-competitive-p97-vcp-inhibitor-induces-apoptosis-and-autophagy-to-suppress-colorectal-cancer-growth 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2300/un-estudio-aleatorizado-que-compara-encorafenib-cetuximab-y-folfiri-frente-a-folfiri-con-o-sin-bevacizumab-en-cancer-colorrectal-con-mutacion-braf-v600e-cohorte-3-del-estudio-breakwater 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2300/a-randomised-study-of-encorafenib-cetuximab-and-folfiri-versus-folfiri-with-or-without-bevacizumab-in-braf-v600e-mutant-colorectal-cancer-breakwater-cohort-3 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2299/la-produccion-a-escala-clinica-de-celulas-tcr-t-durante-10-dias-utilizando-il-2-7-15-y-tgf-promueve-tempranamente-fenotipos-de-memoria-y-similares-a-celulas-residentes-en-los-tejidos-y-una-robusta 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2299/clinical-scale-10-day-tcr-t-cell-manufacturing-using-il-2-7-15-and-tgf-promotes-early-memory-and-tissue-resident-like-phenotypes-and-robust-antitumor-activity-in-vitro 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2298/superacion-de-la-resistencia-adaptativa-al-bloqueo-de-krasg12d-en-el-cancer-de-pancreas-mediante-la-inhibicion-de-la-via-de-senalizacion 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2298/overcoming-adaptive-resistance-to-krasg12d-blockade-in-pancreatic-cancer-through-vertical-pathway-inhibition 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2287/estudio-computacional-de-los-complejos-supramoleculares-de-actinonina-cucurbiturilo-8-para-la-terapia-del-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2287/computational-study-of-actinonin-cucurbit-8-uril-supramolecular-complexes-for-colorectal-cancer-therapy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2286/secuenciacion-rapida-de-proxima-generacion-in-situ-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2286/rapid-on-site-next-generation-sequencing-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2281/la-senalizacion-de-cxcr3-favorece-el-reclutamiento-de-celulas-t-delta-one-y-la-eficacia-antitumoral-en-el-cancer-colorrectal 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2281/cxcr3-signaling-promotes-delta-one-t-cell-recruitment-and-antitumor-efficacy-in-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2278/analisis-integrativo-de-biomarcadores-circulantes-del-cancer-colorrectal-mediante-la-combinacion-de-espectroscopia-de-infrarrojo-medio-y-metabolomica-dirigida 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2278/integrative-analysis-of-circulating-biomarkers-of-colorectal-cancer-combining-mid-infrared-spectroscopy-and-targeted-metabolomics 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2277/accion-fotocitotoxica-de-un-colorante-cianinico-con-dos-cromoforos-formacion-del-radical-anion-superoxido 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2277/photocytotoxic-action-of-cyanine-dye-with-two-chromophores-formation-of-superoxide-anion-radical 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2274/dirigirse-a-la-proteina-bmx-en-el-cancer-mecanismos-moleculares-y-estrategias-terapeuticas-emergentes 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2274/targeting-the-bmx-in-cancer-molecular-mechanisms-and-emerging-therapeutic-strategies 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2273/descifrando-el-microbioma-avances-en-el-microambiente-intestinal-dirigidos-por-inteligencia-artificial-para-lograr-avances-en-la-terapia-oncologica-personalizada 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2273/decoding-the-microbiome-artificial-intelligence-targeted-gut-microenvironment-breakthroughs-in-personalized-cancer-therapy 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2272/metabolomica-asistida-por-analisis-transcriptomico-para-revelar-caracteristicas-metabolicas-y-biomarcadores-potenciales-del-cancer-colorrectal-de-aparicion-temprana 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2272/metabolomics-assisted-by-transcriptomics-analysis-to-reveal-metabolic-characteristics-and-potential-biomarkers-of-early-onset-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2271/parametros-de-la-fdg-pet-tc-para-diferenciar-entre-alta-y-baja-inestabilidad-de-microsatelites-en-el-cancer-colorrectal-una-revision-sistematica-y-metaanalisis 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2271/fdg-pet-ct-parameters-for-distinguishing-high-and-low-microsatellite-instability-in-colorectal-cancer-a-systematic-review-and-meta-analysis 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2270/estrategias-actuales-y-nuevos-enfoques-de-la-inmunoterapia-en-el-cancer-colorrectal-con-estabilidad-microsatelital-un-articulo-de-revision 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2270/current-strategies-and-emerging-paradigms-of-immunotherapy-in-microsatellite-stable-colorectal-cancer-a-review-article 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2269/eficacia-del-bloqueo-dual-kras-g12d-egfr-frente-a-combinaciones-triples-en-modelos-derivados-de-pacientes-de-cancer-colorrectal-con-mutacion-kras-g12d 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2269/efficacy-of-dual-kras-g12d-egfr-blockade-versus-triple-combinations-in-patient-derived-models-of-kras-g12d-mutant-colorectal-cancer 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2265/un-estudio-exploratorio-in-vitro-de-la-citotoxicidad-y-el-perfil-de-citoquinas-de-las-celulas-asesinas-inducidas-por-citoquinas-cik-contra-las-celulas-de-cancer-colorrectal-crc-hct-15 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2265/an-exploratory-in-vitro-study-of-cytotoxicity-and-cytokine-profiling-of-cytokine-induced-killer-cik-cells-against-hct-15-colorectal-cancer-crc-cells 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2264/superando-las-barreras-inmunologicas-mediadas-por-pequenas-vesiculas-extracelulares-en-el-microambiente-tumoral-mediante-peptidos-pegilados-que-se-pueden-activar-estrategicamente 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2264/combating-small-extracellular-vesicle-mediated-immunological-barriers-in-the-tumor-microenvironment-via-strategically-activatable-pegylated-peptides 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2263/conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-diseno-molecular-avances-preclinicos-y-desafios-traslacionales 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2263/antibody-drug-conjugates-in-colorectal-cancer-molecular-design-preclinical-advances-and-translational-challenges 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2262/sintilimab-mas-fruquintinib-con-o-sin-radioterapia-como-tratamiento-de-tercera-linea-para-el-cancer-colorrectal-con-metastasis-hepaticas-protocolo-de-estudio-para-un-ensayo-aleatorizado-multicentrico 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2262/sintilimab-plus-fruquintinib-with-or-without-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases-study-protocol-for-a-randomized-controlled-multicenter-phase-ii-trial 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2256/efecto-de-la-terapia-antitumoral-previa-dirigida-contra-el-egfr-y-de-la-caracterizacion-inicial-del-ctdna-en-la-eficacia-de-pertuzumab-mas-trastuzumab-en-el-cancer-colorrectal-metastasico-con 2026-06-18 monthly 0.5 https://crcwarriors.org/articulo/2256/effect-of-prior-anti-egfr-therapy-and-baseline-ctdna-profiling-on-the-efficacy-of-pertuzumab-plus-trastuzumab-in-her2-amplified-metastatic-colorectal-cancer-an-integrated-analysis-of-triumph-mypathway 2026-06-18 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-06-17 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-06-15 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-06-18 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-06-13 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-06-01 monthly 0.4